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ABSTRACT 
 
 
PANcreatic-DERived factor (PANDER, FAM3B) has been shown to 
regulate glycemic levels via interactions with both pancreatic 
islets and the liver. Although PANDER is predominantly expressed 
from the endocrine pancreas, recent work has provided sufficient 
evidence that the liver may also be an additional tissue source 
of PANDER production.  At physiological levels, PANDER is 
capable of disrupting insulin signaling and promoting increased 
hepatic glucose production.  As shown in some animal models, 
strong expression of PANDER, induced by viral delivery within 
the liver, induces hepatic steatosis. However, no studies to 
date have explicitly characterized the transcriptional 
regulation of PANDER from the liver. Therefore, our 
investigation elucidated the nutrient and hormonal regulation of 
the hepatic PANDER promoter.  Initial RNA-ligated rapid 
amplification of cDNA ends identified a novel transcription 
start site (TSS) approximately 26 bp upstream of the PANDER 
translational start codon not previously revealed in pancreatic 
β-cell lines. Western evaluation of various murine tissues 
demonstrated robust expression in the liver and brain.  Promoter 
analysis identified strong tissue-specific activity of the 
x 
PANDER promoter in both human and murine liver-derived cell 
lines. The minimal element responsible for maximal promoter 
activity within hepatic cell lines was located between -293 to -
3 of the identified TSS.  PANDER promoter activity was inhibited 
by both insulin and palmitate, whereas glucose strongly 
increased expression. The minimal element was responsible for 
maximal glucose-responsive and basal activity. Co-transfection 
reporter assays, chromatin-immunoprecipitation (ChIP) and site-
directed mutagenesis revealed that the carbohydrate-responsive 
element binding protein (ChREBP) increased PANDER promoter 
activity and interacted with the PANDER promoter.  E-box 3 was 
shown to be critical for basal and glucose responsive 
expression.  In summary, in-vitro and in-vivo glucose is a 
potent stimulator of the PANDER promoter within the liver and 
this response may be facilitated by ChREBP.   
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CHAPTER ONE: INTRODUCTION 
 
 
Type 2 Diabetes 
Epidemiology of T2D. Worldwide, diabetes mellitus affects more 
than 285 million adults, approximately 6.4% of the world 
population and estimates suggest that this number could soar to 
439 million by the year 2030 [1]. In the United States alone, 
approximately 25.8 million people, 8.3% of the population, were 
affected by Diabetes in 2011 [2]. T2D, also known as “adult-
onset” diabetes, accounts for roughly 90-95% of all diagnosed 
cases and has reached epidemic status in the US. The economic 
costs of diabetes are staggering, with costs in the United 
States at approximately $174 billion dollars in 2007 alone [2]. 
More importantly, diabetes takes a massive toll on human lives 
with uncontrolled diabetes being associated with a substantially 
increased risk of premature morbidity and mortality [3, 4]. 
Diabetics are at an increased risk of cardiovascular disease, 
renal failure, blindness and amputation, leading to a decreased 
quality of life and, quite often, a premature death. The 
enormous societal and personal burden of the worsening diabetes 
epidemic underscores the importance of understanding the 
2 
signaling proteins that contribute to T2D development and 
progression. 
 
Clinical and molecular characteristics of T2D. T2D, also called 
“non-insulin dependent” diabetes, encompasses complex group of 
metabolic disorders that are characterized by increased blood 
glucose levels caused by insulin resistance and/or impaired 
insulin action [5, 6]. This can be due to impaired β-cell 
function or impaired sensitivity of target tissues to the action 
of secreted insulin [7, 8]. Under normal conditions, pancreatic 
β-cells produce insulin which is then stored in vacuoles until 
blood glucose levels become elevated. At this time, insulin is 
released into the blood stream and signals the uptake of glucose 
into skeletal muscle. Insulin signals for liver and skeletal 
muscle to convert glucose into its storage form, glycogen. 
Insulin action also results in the suppression of hepatic 
glucose production (HGP) and release of fatty acids from 
adipocytes [6, 9]. In the diabetic state, impaired secretion of 
insulin from the β-cells causes decreased insulin signaling and 
results in a lack of glucose uptake causing hyperglycemia. 
Impaired ability of target tissues to respond to insulin results 
in impaired glucose tolerance (the ability for the body to clear 
glucose form the blood), increased hepatic glucose production 
and fatty acid release from adipose tissue. Meanwhile, the 
3 
pancreas continues to produce insulin to combat the 
hyperglycemia, resulting in a hyperinsulinemic state. The 
resultant high levels of glucose and fatty acids in the blood 
causes a positive feedback loop furthering insulin resistance 
and resulting in worsened hyperglycemia, hyperinsulinemia and 
hyperlipidemia [8]. The pathophysiology of T2D is outlined in 
Figure 1. The lifestyle factors that contribute to the 
development and progression of T2D include high fat diet, 
inactivity and central adiposity, and have been studied 
extensively. New research into the molecular mechanisms of 
insulin resistance and β-cell dysfunction has underscored the 
importance of cytokines and other proteins in the development 
and treatement of T2D.  
 
Cytokines in T2D. There has been a tremendous surge in research 
surrounding the importance of cytokines in the development and 
progression of diabetes. Abnormal cytokine profiles within the 
serum and pancreatic β-cells has been shown to play a role in 
the progression of both T1D and T2D [10]. Several cytokines have 
been implicated in the progression of T2D specifically, 
including: Interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-
α), leptin and resistin. Chronic exposure of liver or muscle 
cells to these four cytokines has been shown to induce the 
expression of suppressor of cytokine-signaling protein 3 (SOCS-
4 
3). SOCS-3 can bind to the insulin receptor (IR) and insulin 
receptor substrate (IRS)-1 and -2, blocking the activation of 
insulin signaling [11, 12]. Furthermore, decreases in 
circulating adiponectin levels have been shown to be associated 
with the progression of β-cell dysfunction and insulin 
resistance in obesity [12]. The role of cytokines in the 
progression of T2D emphasizes the importance of further research 
into novel cytokines and factors that may be influencing 
cytokine induction and potentially increasing insulin 
resistance. 
 
T2D and the liver. The liver is the main source of glucose 
output during the fasting state, controlling both glycogenolysis 
(the breakdown of glycogen into glucose for release into the 
bloodstream) [13] and gluconeogenesis (the generation of new 
glucose molecules from non-carbohydrate sources) [14]. As a 
result, the liver is one of the most significantly dysregulated 
organs in T2D due to the disruption of insulin signaling within 
the cells of the liver. This disruption leads to the failure to 
suppress HGP and further impairment of glucose tolerance [15, 
16]. The failure of insulin to suppress HGP occurs through two 
separate mechanisms. Under normal conditions, insulin binds to 
its receptor directly on the liver cell membrane suppressing 
gluconeogenesis through inhibiting transcription of 
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gluconeogenic enzymes glucose 6-phosphatase (G6P-ase) and PEPCK 
by nuclear exclusion of the Forkhead Box Protein O1 (FOXO1) 
transcription factor [17]. In addition to directly acting on the 
liver, insulin also inhibits the secretion of glucagon from 
pancreatic α-cells though a mechanism that is yet to be fully 
elucidated. Recent research suggests this inhibition may be 
related to insulin-dependent activation of GABAA receptors via an 
Akt kinase-dependent pathway leading to hyperpolarization of the 
α-cell and suppression of glucagon secretion [18]. Impaired 
insulin signaling has also been shown to result in the failure 
of adipocytes to suppress lipolysis (the breakdown of lipids 
though the hydrolysis of triglycerides into glycerol and free 
fatty acids). Insulin normally suppresses lipolysis within the 
adipocytes via both Akt-dependent and Akt-independent mechanisms 
[9, 19]. In the insulin resistant state, free fatty acids are 
released from the adipocytes and subsequently taken up by 
hepatocytes, thereby increasing both free fatty acid (FFA) 
content in the blood and within the liver itself (fatty liver) 
[20]. The increase in FFAs has also been shown to promote 
gluconeogenesis [21, 22] and contribute to further insulin 
resistance [23, 24], creating a dangerous positive feedback loop 
[25]. The dysregulation of these pathways in the diabetic state 
and their subsequent effect on overall liver metabolism has also 
led to research into T2D’s association with other liver-related 
6 
metabolic diseases and, in particular, Non-alcoholic Fatty Liver 
Disease, which often occurs concurrently with and as a precursor 
to T2D [26].  
 
Non-alcoholic Fatty Liver Disease 
Epidemiology of NAFLD. Chronic liver disease (CLD) is the 12th 
leading cause of death in the United States [27]. Non-alcoholic 
fatty liver disease (NAFLD) is the most common form of CLD 
worldwide and is present in approximately 30% of the population 
of the United States [28-30]. NAFLD is characterized by deposits 
of fat within the liver, or steatosis, which have been caused by 
factors outside of excessive alcohol use. This disease 
encompasses a range of liver conditions from minor hepatic 
steatosis to the high aggressive non-alcoholic steatohepatitis 
(NASH). NASH is known to cause hepatocyte injury, inflammation 
and fibrosis, eventually leading to the potential complications 
of liver cirrhosis and hepatocellular carcinoma [28]. Overall, 
NAFLD is associated with several serious comorbidities 
including: insulin resistance, obesity, hypertension and T2D 
[31].  
 
Clinical and molecular characteristics of NAFLD. While the exact 
cause of NAFLD is unknown, the progression of the disease has 
been linked with multiple tissues and, in particular, insulin 
7 
resistance within the liver and adipose tissues. The activated 
lipogenic signaling pathways associated with hepatic insulin 
resistance have been shown to be frequently associated with 
hepatic steatosis [32]. In addition, the insulin-resistant state 
causes an increase in lipolysis within the adipose tissues due 
to insulin’s inability to suppress the activity of lipase. This 
leads to an increase in free fatty acids (FFA) within the blood 
serum, resulting in increased hepatic FFA uptake and the 
increased presence of triglyceride deposits within the liver 
[33]. Given the clear involvement of multiple tissues and the 
association with the increasing rates of T2D and obesity 
throughout the world, the effort to determine and characterize 
the molecular mechanisms by which NAFLD develops and progresses 
has become integral to the overall understanding and treatment 
of the disease. 
 
Cytokines in NAFLD. The role of cytokines in the development and 
progression of NAFLD and its subsequent comorbid conditions has 
been a major subject of research in recent years. Several 
cytokines have been implicated in the development of NAFLD and 
subsequent insulin resistant phenotype. Tumor Necrosis Factor α 
(TNF-α) has been extensively researched and appears to play a 
central role in obesity-associated insulin resistance and fatty 
liver [34]. Levels of TNF-α, circulating and within the liver 
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and adipocytes, is increased in animal models of obesity [35, 
36]. Treatment of cells in vitro with TNF-α has been shown to 
inhibit insulin action [37] and animals lacking in TNF-α or its 
receptors have been shown to have improved insulin sensitivity 
in obesity models [38]. Certain TNF-α polymorphisms have also 
been shown to be associated with levels of susceptibility for 
developing insulin resistance and NAFLD in humans [39]. In 
addition to TNF-α, several other signaling molecules have been 
implicated in the development and progression of NAFLD, 
including: Jun N-terminal kinase (JNK) [40], IL-6 [41], 
adiponectin [42], and IL-8 [43]. Further study into these 
signaling molecules, and the characterization of novel factors, 
and their complex interaction leading to the development and 
progression of NAFLD and associated insulin resistance will be 
integral to the overall understanding of the disease and its 
comorbid conditions, as well as its prevention and treatment. 
 
Type 1 Diabetes 
Type 1 Diabetes (T1D), also formally referred to as “insulin-
dependent” or “juvenile-onset” diabetes, accounts for 5-10% of 
all cases of diabetes [44]. Approximately 78,000 children are 
diagnosed annually with T1D around the world [45]. Diagnosis in 
the United States is expected to increase by an estimated 144% 
over the next 35 years from the current prevalence of 2.13/1000 
9 
to 5.2/1000 by the year 2050 [46]. The estimated burden of T1D 
in the young in the U.S. (<20 years) and Europe (<15 years) is 
expected to reach 400,000 by the year 2020 [46-48]. T1D is 
characterized by hyperglycemia caused by an autoimmune response 
resulting in the destruction of pancreatic β-cells [49]. 
Although onset of T1D can occur at any age, diagnosis is 
typically made during youth or young adulthood [50]. While the 
exact cause of this immune destruction remains elusive, recent 
research has made great strides in elucidating potential factors 
contributing to the development of this disease and its 
increased incidence in recent years. Possible explanations for 
the increase in diagnosis include: improved hygiene leading to 
reduced exposure to microbes and a resultant dysfunction in 
immune response [51, 52] and increased body size overloading β-
cells with insulin demand [53]. Much of the recent research into 
molecular factors associated with the development of T1D has 
revolved around the identification of genetic risk factors [54, 
55] and biomarkers within the metabolome [56, 57]. Currently, 
the primary course of treatment for T1D is regular glucose 
monitoring and supplemental insulin and has been since the 
discovery of insulin in 1921 [58]. While supplemental insulin 
has proved a successful treatment for many patients, it is not 
without its drawbacks, including acute morbidity and mortality 
as well as serious complications [59, 60]. Thus, further 
10 
research into the molecular factors, which could provide insight 
into early diagnosis and more effective treatment, will be of 
the utmost importance over the next several years as T1D 
prevalence continues to rise.  
 
Initial Discovery of Pancreatic-Derived Factor 
Pancreatic-Derived Factor (PANDER) is a recently characterized 
secreted hormone. The discovery of PANDER was made through the 
use of the algorithm Ostensible Recognition of Folds (ORF) in a 
search for novel cytokines based on predicted secondary 
structure [61]. The predicted secondary structure of PANDER 
revealed the four helix bundle with up-up-down-down topology 
that is typical of many other common cytokines such as IL-2, -10 
and -13 [62]. This algorithm identified a novel family of 
proteins predicted to display this cytokine-like secondary 
structure: family with sequence similarity 3 (FAM3). The FAM3 
family consists of four members: FAM3A, FAM3B, FAM3C, FAM3D 
[63]. 
 
PANDER Structure 
Although initial data suggested that FAM3 family members had a 
cytokine like structure, recent data suggests that the FAM3 
family represents a novel class of signaling molecules, with 
PANDER exhibiting a globular β-β-α fold (Figure 2). This unique 
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structure is conserved among the FAM3 proteins and is unlike 
that of any known cytokine [64]. The amino acid sequence 
homology among the four FAM3 members is approximately 31.6-
53.3%, with there being no significant homology to any other 
known cytokines [65]. FAM3B was later coined as PANDER due to 
its primary expression in the endocrine pancreas. PANDER has 
also been shown to be expressed in lower levels in the prostate, 
intestine, and ovaries [65-67]; although the function of PANDER 
in these other tissues is unknown. Human PANDER contains 235 
amino acids and shares 78% primary sequence homology, including 
4 conserved cysteines, with its murine homolog [68]. Given 
PANDER’s structure, it is reasonable to surmise that PANDER 
plays an important role in cellular signaling pathways within 
the pancreas and in the liver. 
 
Animal Models of PANDER 
Several animal models have been derived to investigate PANDER’s 
potential role in glucose regulation, with differing results. 
One group evaluated hepatic PANDER overexpression achieved 
through adenoviral delivery. This model revealed fasting 
hyperglycemia, hyperinsulinemia and elevated corticosterone 
levels [69].  Another group derived a similar adenoviral 
delivered overexpressing model with different results and did 
not observe glucose intolerance, fasting glycemia, or elevated 
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corticosterone levels.  However, liver and serum triglyceride 
content was increased compared to WT mice along with serum 
insulin levels [67].   
 
Pancreas specific PANDER overexpressor. To help elucidate the 
sources of these discrepancies and provide more conclusive 
evidence of the effect of PANDER overexpression, our laboratory 
has created and phenotyped the only transgenic mouse model 
(PANTG) with tissue-specific PANDER overexpression and secretion 
from the endocrine pancreas to further elucidate the physiologic 
role of pancreas-secreted PANDER in-vivo. Male PANTG mice 
display elevated fasting glucose and insulin. Hyperinsulinemic-
euglycemic clamp studies also revealed that PANTG displays 
increased hepatic glucose production and insulin resistance 
compared to WT counterparts [70]. Our metabolic phenotyping and 
proteomic analysis strongly indicate that endocrine specific 
overexpression of PANDER impacts hepatic glycemic output and 
lipid regulation [67].  
 
PANDER knockout. In addition to the creation of a PANDER 
overexpressor, we also have access to a global PANDER knockout 
mouse (PANKO). In this mouse, the PANDER gene has been disrupted 
by replacing the region containing the first two exons, 
transcriptional start site and the secretion signal peptide, 
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with the neomycin gene. This results in the complete loss of 
PANDER expression in all tissues. The PANKO mouse displays 
glucose intolerance during a glucose tolerance test due to 
impaired insulin secretion and abnormal Ca2+ handling within 
pancreatic islets [67]. In addition, during hyperinsulinemic-
euglycemic clamp studies, PANKO displayed lower hepatic glucose 
production (HGP) and increased HGP suppression when compared to 
wild-type [67], as well as improved hepatic insulin sensitivity 
[71]. This phenotype was more significant in male PANKO mice, 
however, females also demonstrated the overall trends in 
enhanced glucose tolerance [71]. These animal models provide 
invaluable evidence of the in vivo effects of overexpressing and 
knocking out PANDER expression, and may prove useful in the 
study of the effects of PANDER on the liver. 
 
PANDER in the Pancreas 
Initial characterization of PANDER’s tissue distribution by 
Northern Blot revealed that both human and murine PANDER are 
highly expressed in the pancreas [65]. Immunohistochemical 
staining has shown PANDER to be localized specifically to the 
islet of Langerhans in the endocrine pancreas, with no 
expression in the exocrine pancreas [68]. PANDER has been shown 
to act on the cells of the pancreas in a number of ways. In 
vitro, overexpression of PANDER or treatment with recombinant 
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PANDER led to apoptosis in rat, mouse and human pancreatic β-
cells [68, 72].  Microarray analysis revealed a significant 
downregulation of cyclin-dependent kinase inhibitor 1A, also 
known as p21. The downregulation of this protein has been shown 
in other cell types to mediate cell death [73]. This analysis 
also revealed activation of caspase-3, which has been shown 
previously to be a central molecular involved in β-cell death in 
autoimmune diabetes [74]. Caspase-3 has also been demonstrated 
to cleave p21, which is important for death-associated cyclin 
A/Cdk2 activation in several cell types [75]. Taken together, 
the decrease in p21 and increase in caspase-3 may be playing a 
role in PANDER-induced cell death in islets [76]. Recent 
research suggests that PANDER has an effect on insulin secretion 
from the endocrine pancreas, leading to changes in glucose 
metabolism. PANDER-deficient mice display glucose intolerance 
and decreased serum insulin levels in response to glucose or 
arginine administration [77]. PANDER-/- islet cells have 
decreased insulin secretion in response to glucose or calcium 
chloride stimulation. Previous data suggest that decreased 
glucose-stimulated insulin secretion in rat models of T2D can be 
attributed to abnormal calcium handling within the islets [78, 
79]. PANDER-/- islets also display an abnormal intracellular 
calcium response during glucose stimulation when compared to 
PANDER+/+ islets [77]. These islets do not display the typical 
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calcium dip during glucose stimulation. This dip has been 
attributed to SERCA sequestration of Ca2+ in db/db murine islets 
[80]. Though SERCA mRNA levels were similar between PANDER-/- and 
wild-type mice, activity was not evaluated and may provide more 
insight into the mechanism behind the abnormal calcium response 
in the absence of PANDER [77]. Overall, these data suggest a 
role of PANDER in regulating insulin secretion in pancreatic 
islets by affecting calcium homeostasis under physiological 
conditions. 
 
PANDER and Insulin 
PANDER is localized to the insulin secretory vesicles in β-
cells, suggesting that it may be cosecreted with insulin [81]. 
Pancreatic β-cell lines treated with glucose saw marked 
increases in both PANDER and insulin in a dose and time 
dependent manner [82]. In fact, several secretagogues and 
inhibitors of insulin secretion were evaluated and it was found 
that stimulators of insulin secretion also induced PANDER 
secretion, while inhibitors repressed PANDER secretion in mouse 
islets and β-cell lines. Correct structure and conformation of 
PANDER is essential for PANDER secretion from β-cells. Misfolded 
PANDER mutants can be produced by and accumulate within the cell 
but are unable to be sorted into insulin secretory granules and 
secreted from the cell [82]. It is unknown how these mutants may 
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be cleared from the cell and/or targeted for degradation. These 
data suggest that the expression and secretion of PANDER and 
insulin within pancreatic β-cells are strongly coupled. PANDER 
has also been shown to localize within α-cells, to a glucagon-
negative granular cytosolic compartment, cytoplasmic granules, 
neuroendocrine vesicles, endoplasmic reticulum (ER), and the 
cis-Golgi [83]. The secretion of PANDER from α-cells can be 
induced by insulin and requires PI3K/Akt signaling via 
stimulation of the insulin receptor [83]. PANDER’s localization 
and action on both α- and β-cells suggest a strong functional 
role of PANDER within the endocrine pancreas; however, given its 
association with insulin and glucose, it stands to reason that 
PANDER may also play a role in other metabolic tissues and, in 
particular, the liver. 
 
PANDER in the Liver 
In vitro saturation binding assays have demonstrated 125I-PANDER 
binding to the liver cell membrane [84]. These results suggest 
that the liver is a novel target tissue of PANDER, although 
PANDER receptor has yet to be identified. In vitro research 
using a human liver-derived cell line (HepG2) indicates PANDER 
suppresses hepatic insulin signaling by decreasing levels of 
tyrosine phosphorylation of insulin receptor (IR) and insulin 
receptor substrate (IRS-1) and repressing the insulin-stimulated 
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activation of PI3K and Akt [84]. Furthermore, it has been shown 
that recombinant murine PANDER treatment induces gluconeogenic 
gene expression and increased glucose production in primary 
cultured mouse hepatocytes [69]. In vivo, mice overexpressing 
PANDER in the pancreatic islets (PANTG) are glucose intolerant 
due to impaired insulin signaling within the liver [69, 77]. 
Recent data from our lab also indicates that hepatic PANDER 
protein is upregulated in the fed state as well as being 
chronically elevated in the PANTG mouse (Figure 3) [70]. These 
data suggest that islet-derived and recombinant PANDER are able 
to target the tissues within the liver and induce hepatic 
glucose production while inhibiting hepatic insulin signaling. 
However, the role that liver-derived PANDER has on hepatic 
insulin signaling has not been well characterized. One study 
showed significant activity of the PANDER promoter within liver-
derived cell lines, even more significant than that of islet-
derived cell lines, although this finding was not explored 
further [66]. This study brings to light the potential 
importance of the liver in PANDER secretion in addition to it 
being a target for PANDER action. A recent study showed that 
PANDER expression in the liver may play a role in promoting 
lipogenesis and downregulating insulin signaling in response to 
insulin stimulation [67]. While recent data has supported liver-
derived PANDER as being an important factor in regulating 
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insulin signaling and hepatic glucose production, the mechanism 
of regulation and functional significance of liver-derived 
PANDER remains largely unexplored. 
 
Proteomic Analysis of PANDER in the Liver 
One means of evaluating the function of PANDER within the liver 
is be examining changes in global protein expression in liver 
tissue when exposed to varying levels of PANDER. Our lab has 
performed initial proteomic analysis of the pancreas-specific 
PANDER overexpressor mouse (PANTG) [70]. Initial 
characterization of the PANTG mouse revealed increased fasting 
and post-prandial glycemic levels in the absence of peripheral 
insulin resistance but the presence of hepatic insulin 
resistance.  We then measured critical hepatic insulin signaling 
molecules via a comprehensive proteomic approach known as stable 
isotope labeling of amino acids in cell culture (SILAC).  This 
quantitative proteomic strategy metabolically labels the entire 
proteome and allows for identification and network elucidation 
by mass spectrometry analysis and has become a highly useful and 
relatively novel tool to identify complex protein mixtures, 
signaling cascades, and regulated protein modifications [85].  
Total protein isolate was prepared from extracted livers from 
PANTG and WT mice (n=6 per group) obtained during fed 
conditions. Isolated liver lysate was prepared from PANTG and WT 
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male mice (n=6 per group) during random fed conditions.  Livers 
were homogenized in TPER buffer (Thermo Fisher Scientific) 
followed by high-speed centrifugation.  Ethanol-treated AML-12 
cells were utilized as a surrogate cell line for protein 
comparison as previously described [85]. The AML-12 cells were 
heavy labeled by culturing in media containing 13C6 L-Lysine-2-HCl 
and 13C6 L-arginine-HCl followed by homogenization in MPER buffer 
(Pierce, Rockford, IL) followed by high-speed centrifugation. 
Supernatants were collected and protein concentration quantified 
(Pierce BCA protein assay). Equivalent amount of liver protein 
was then spiked with equal mass of protein from AML-12’s. The 
spiked mixture was solubilized using FASP protein digestion kit 
(Protein Discovery). The six samples derived from PANTG and WT 
livers, respectively, were then batched and both samples were 
desalted prior to fractionation using an automated CXS column. 
Nine fractions were selected for both PANTG and WT mice and 
subsequently dissolved in 1% aqueous formic acid for evaluation 
by mass spectrometry (LTQ Orbitrap). Data was normalized and 
analyzed using the Ingenuity Pathway Analysis (IPA) program.  A 
total of 1640 proteins were confidently identified and 
quantitated. Relative changes in the levels of identified 
proteins were determined by the ratio of PANTG to that of WT and 
normalized to Tubulin B5. Of those, 88 protein groups were 
upregulated and 9 were downregulated (P < 0.05 for both groups). 
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The distribution of ratios of all quantitated proteins indicated 
excellent representation of the proteome between PANTG and WT 
ratio relative to that of AML-12 cells. Approximately 1,640 
proteins were identified and quantitated.  Data was normalized 
and analyzed using the Ingenuity Pathway Analysis (IPA) program. 
Relative changes in the levels of identified proteins were 
determined by the ratio of PANTG to that of WT and normalized to 
proteomic expression of Tubulin B5. Of those, 88 protein groups 
were up-regulated and 9 were down-regulated (P < 0.05 for both 
groups).  IPA of the differentially expressed proteins 
identified lipid metabolism as one of the top associated network 
functions as significantly up-regulated (20 total proteins with 
P=9.46x10-6) with an overall score of 57 (Score of 2 is 
significant) (Figure 4A). Further IPA analysis identified 
quantity of triacylglycerol to be in a predicted increased state 
(z-score of 2.4) with a genetic network of interacting proteins 
consisting of consisting of: fatty acid binding protein (FABP-
1), protein kinase A type II-beta regulatory subunit (PRKAR2B), 
phosphoenol-pyruvate carboxykinase (PEPCK), sterol carrier 
protein (SCP2), acetyl CoA synthetase (ACSL1), and 
ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5) 
(Figures 4B and 4C).  Of those identified to promote increased 
triglyceride production, 4 of which were revealed to molecularly 
interact as determined by IPA (Figure 4C). Overall, SILAC 
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identified a proteomic profile within the PANTG liver of 
increased lipid metabolism and increased PEPCK (gluconeogenic) 
expression supporting the observed results obtained with both 
the HEC and phenotypic analysis [70]. The SILAC approach used in 
these preliminary studies may be useful in further evaluating 
the function of PANDER within the liver. 
 
PANDER Promoter 
PANDER promoter activity has been studied previously, including 
the identification of a transcriptional start site in the β-TC3 
mouse insulinoma cell line. The transcriptional start site was 
identified 520 bp upstream of the translational start codon by 
5’-RLM-RACE [66].  RLM-RACE is a PCR-based technique that is 
designed to amplify cDNA from full-length, capped mRNA. The 
resultant cDNA can then be sequenced to identify a 
transcriptional start site [86]. Further analysis of the 
promoter sequence revealed three A-box elements and three E-box 
elements within the -338/+491 promoter region (relative to the 
transcriptional start site). In order to assess promoter 
activity within specific tissues and under certain conditions, 
several promoter constructs were created. These constructs 
contain truncated regions of the PANDER promoter conjugated to 
the luciferase gene within the pGL3-basic plasmid. This allowed 
the evaluation of PANDER promoter activity using a standard 
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luciferase assay from transfected cell lysates. The PANDER 
promoter constructs that were originally created included the 
following regions: -2338/+491, -1338/+491, -338/+491 and 
+1/+491. The PANDER promoter region was flanked with KpnI and 
MluI restriction sites via PCR to aid in the insertion of the 
promoter construct into the pGL3-basic luciferase construct 
[66]. Later, several more promoter construct variations were 
created for further evaluation of promoter activity, including: 
-338/+1, +1/+100, +1/+200, +100/+491, +200/+491. Using these 
promoter constructs, the PANDER promoter was found to be highly 
active in islet-derived cell lines as well as a murine liver-
derived cell line (BNLCL2), although the significance of 
promoter activity in the liver was not further explored [66]. 
This study did find, however, that the PANDER promoter was 
glucose-responsive in islet-derived cell lines. Further study 
revealed that the glucose responsiveness of the PANDER promoter 
in islets may be regulated primarily through transcription 
factor binding to A-box elements on the promoter. Pancreatic 
Duodenal Homeobox-1 (PDX-1) was found to produce the most 
significant increase PANDER promoter activity among the 
transcription factors investigated, through its binding to A-box 
elements in response to glucose stimulation [87]. While these 
data provide some insight into regulation of the PANDER promoter 
in the pancreas, there have been no studies investigating the 
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regulation of the PANDER promoter in the liver, despite PANDER’s 
potentially important role in regulating hepatic insulin 
signaling and glucose production. A previous study has 
identified three E-box elements with the +200/+491 region of the 
PANDER promoter, which may serve as binding sites for glucose-
induced transcription factors [82].  The PANDER promoter 
contains several potential nutrient and hormonal binding sites 
that have yet to be characterized and our studies will be the 
first to reveal the potential mechanism of PANDER expression 
within the liver.    
 
Metabolic Signaling in the Liver 
In the fed state, blood glucose concentration is increased which 
results in the rapid release of insulin from pancreatic β-cells. 
This induces the anabolic pathways in insulin’s target tissues 
and, in particular, the liver. The insulin signaling cascade is 
initiated when insulin binds to the extracellular β-subunits of 
the dimerized insulin receptor on the liver cell membrane [88]. 
This binding induces the autophosphorylation of tyrosine 
residues at the intracellular β-subunit of the insulin receptor. 
IRS proteins bind to the phosphorylated receptor via their 
phosphotyrosine binding (PTB) domain and are subsequently 
phosphorylated on multiple residues creating docking sites for 
src homology 2 domain containing proteins such as insulin 
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receptor-1, insulin receptor-2, and phosphoinositide-3 (PI-3) 
kinase. This signal is then transferred onto further molecules 
such as Akt and protein kinase C (PKC) to potentiate various 
insulin-stimulated anabolic actions. Akt action inhibits 
glycogen phosphorylase, thereby inhibiting glycogenolysis [89]. 
Akt also phosphorylates FOXO1, which creates binding sites for 
14-3-3, preventing DNA binding and transcription of 
gluconeogenenic proteins, such as PEPCK and G6Pase [90]. PKC 
activates sterol regulatory element binding protein 1c (SREBP-
1c) which, in turn, activates transcription of lipogenic (FAS) 
and glycolytic proteins (glycokinase (GK) [91], pyruvate kinase 
(PK) [92]) and inhibits gluconeogenic factors (PEPCK, G6Pase 
[93]). It has also been shown that another protein, carbohydrate 
responsive element binding protein (ChREBP) works alongside 
SREBP-1c to synergistically activate these pathways [94]. 
Overall, the hepatic action of insulin results in three primary 
functions regulation of lipid metabolism, activation of glucose 
storage and shutdown glucose production and output, and 
inhibition of gluconeogenesis. The mechanism of these actions is 
outlined in Figure 5. 
 
Carbohydrate Responsive Element Binding Protein 
Several E-box elements have been identified within the +200/+491 
region of the PANDER promoter. These E-box elements may comprise 
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a carbohydrate responsive element (ChoRE) where binding of 
carbohydrate responsive element binding protein (ChREBP) could 
occur [95]. ChREBP is a transcription factor that has been shown 
to induce transcription of several genes associated with 
carbohydrate metabolism in response to glucose stimulation 
within the liver [96-98]. Under non-stimulatory conditions, 
ChREBP is phosphorylated and sequestered within the cytosol by 
association with the regulatory protein 14-3-3. Influx of 
glucose with the hepatocyte leads to an increase in xylulose 5-
phosphate (Xu-5-P) levels, subsequently activating protein 
phosphatase 2A (PP2A). PP2A dephosphorylates ChREBP, allowing it 
to be translocated to the nucleus where it dimerizes with max-
like protein X (Mlx) and binds to the ChoRE of target genes such 
as FAS, L-PK and ACC [98, 99]. Increased levels of glucagon and 
fatty acids lead to increased activity of PKA and AMPK, 
respectively, which phosphorylate ChREBP and promote its 
exclusion from the nucleus (Figure 6) [98, 100, 101]. Studies 
have revealed that glucose may be responsible for inducing 
lipogenesis in the liver through this stimulation of ChREBP 
[102, 103]. These studies showed, using primary rat hepatocytes, 
that insulin and high glucose levels resulted in a significant 
increase in acetyl-coA carboxylase 1(ACC1), fatty acid synthase 
(FAS) and S14, all of which are targets of ChREBP and are 
involved in the induction of lipogenesis in the liver [103]. In 
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addition to lipogenesis, ChREBP appears to be involved in the 
induction of liver glycolysis. ChREBP has been found to bind and 
induce the transcription of the liver-type pyruvate kinase (LPK) 
gene, which is essential in the induction of glycolysis in the 
liver [104]. In vivo research showed that mice deficient in 
ChREBP had decreased levels of LPK and reduced liver glycolysis, 
in addition to a marked reduction in lipogenesis [102]. Still 
another study found that ob/ob mice treated with recombinant 
adenovirus containing shRNA against ChREBP displayed 
improvements in both hepatic steatosis and insulin sensitivity 
[105]. Given the potential ChoRE within the PANDER promoter and 
its important role in glucose-induced lipogensis in the liver, 
ChREBP may serve as an important stimulator of PANDER expression 
in the liver in response to increased levels of glucose. 
 
PANDER and Metabolic Disease 
PANDER’s potential role in metabolic disease is multifaceted. It 
has been shown to be involved in all three major hallmarks of 
T2D: hyperglycemia, hyperinsulinemia and hyperlipidemia. 
Research suggests that PANDER may be co-secreted with insulin in 
the hyperglycemic state [81, 82] wherein it binds to the liver 
cell membrane and contributes to hepatic insulin resistance, 
lipogenesis [84] and gluconeogenesis [69]. Hepatic 
overexpression of PANDER has resulted in various pleiotropic 
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effects producing a selective hepatic insulin resistant 
phenotype of impaired hepatic insulin signaling yet increased 
hepatic triglycerides and production of very low-density 
lipoprotein (VLDL)-TG [69]. Similar results were observed in a 
PANDER transgenic pancreatic β-cell specific overexpressing 
model that exhibited decreased glucose tolerance, hepatic 
insulin resistance yet increased hepatic TG concentration [70]. 
Taken together, the display of these various animal model 
phenotypes that have been further supported by PANDER knockout 
studies [70, 71, 77, 106] has potentially implicated PANDER’s 
involvement in the initiation and/or progression of T2D [107] 
and NAFLD [108]. Additionally, a very recent study demonstrated 
that PANDER levels within patients with metabolic syndrome were 
increased and highly correlated with severity of the metabolic 
syndrome [109]. These factors, combined with evidence showing 
that PANDER may induce apoptosis in pancreatic β-cells [68, 76], 
may also implicate PANDER as a potential biomarker in T1D. 
Despite this critical importance, the hepatic regulation of 
PANDER has not been examined particularly in the context of 
which nutrient or hormonal secretagogues or transcription 
factors govern expression.  Therefore, the work contained within 
this dissertation is the first to characterize the 
transcriptional regulation of hepatic PANDER.    
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Hypothesis and Specific Aims 
In 2011, approximately 25.8 million people, 8.3% of the 
population, were affected by Diabetes mellitus in the United 
States [2]. T2D accounts for roughly 90-95% of all diagnosed 
cases and has reached epidemic status in the US. The economic 
and human costs of T2D are staggering with uncontrolled diabetes 
being associated with a substantially increased risk of 
premature morbidity and mortality [3, 4]. The worsening diabetes 
epidemic underscores the importance of understanding the 
mechanisms by which diabetes develops and progresses. 
Pancreatic-Derived Factor (PANDER) is a novel cytokine-like 
hormone that interacts with the endocrine pancreas and the liver 
and is associated with the regulation of insulin secretion and 
hepatic glucose production [82]. Islet-derived and recombinant 
PANDER has been shown to decrease hepatic insulin signaling and 
increase hepatic glucose production, both in vitro and in vivo 
[77, 84]. PANDER’s role in regulating insulin signaling and 
glucose production suggests that it may play an important role 
in the development and progression of T2D. While PANDER has been 
studied almost entirely within the context of secretion from 
pancreatic islets, a recent and novel study indicates that 
liver-derived PANDER may also play an important role in 
regulating insulin signaling. Liver-derived PANDER has been 
shown to induce lipogenesis and insulin resistance in response 
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to insulin stimulation and play a potential role in the 
deleterious cascade of selective hepatic insulin resistance 
[67]. This novel finding emphasizes the importance of further 
evaluating PANDER’s role within the liver. The proposed project 
will seek to elucidate the mechanism by which PANDER is 
transcriptionally regulated in the liver. We hypothesize that 
PANDER expression within the liver can be induced by both 
nutrient and hormonal secretagogues and is tightly regulated by 
transcription factor binding to the PANDER promoter. A better 
understanding of how PANDER expression is regulated in the liver 
will lead to further characterization of mechanisms by which 
insulin signaling and glucose production become dysregulated in 
human disease, in particular T2D. Specifc Aims are depicted in 
Figure 7. 
 
Specific Aim 1: Determine secretagogues responsible for PANDER 
transcriptional expression  
1.1 Measure the role of insulin, glucose and palmitate on 
PANDER promoter activity via luciferase assay 
1.2 Identify the hepatic transcriptional start site within 
the PANDER promoter using RNA Ligase Mediated Rapid 
Amplification of cDNA Ends (RLM-RACE) 
1.3 Determine the intracellular distribution of PANDER 
within the liver 
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Specific Aim 2: Identify transcriptional factors mediating 
PANDER expression in the liver  
2.1 Perform computational search to identify putative 
transcriptional factors 
2.2 Identify critical transcriptional factors by co-
transfection experiments 
2.3 Determine functionality of critical transcriptional 
factor binding regions 
Specific Aim 3: Examine PANDER induced transcription factor 
profile and canonical pathways within primary hepatocytes.  
3.1 Perform PANDER treatment and transcription factor 
array on primary hepatocytes 
3.2 Identify differentially regulated transcription 
factors and overall canonical functions via Ingenuity 
Pathway Analysis 
 
A single report has suggested that liver-derived PANDER may play 
a role in hepatic insulin signaling and glucose production, as 
well as lipogenesis. These results implicate PANDER in the 
development and progression of T2D [107, 110]. This research 
will lead to a better understanding of how PANDER is regulated 
within the liver and how liver-derived PANDER impacts hepatic 
signaling in response to secretagogue stimulation. We will also 
gain valuable insight as to the potentially differing effects of 
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intracellular and extracellular PANDER within the liver. The 
data obtained from this research will further the knowledge of 
how liver-derived PANDER plays a role in metabolic signaling. 
Elucidating the mechanism by which hepatic PANDER is regulated 
may provide novel therapeutics for the treatment of T2D. 
 
Innovation 
The study of PANDER over the past decade has focused primarily 
on its role in the context of its secretion from the endocrine 
pancreas. However, recent data indicates that liver-derived 
PANDER may play an important role in hepatic insulin signaling, 
lipogenesis and hepatic glucose production [67, 69, 77].  In 
addition, PANDER may serve as a critical cofactor in the onset 
and progression of T2D.   Despite PANDER’s suggested role within 
the liver, the study of the regulation of hepatic PANDER 
expression has not been explored. The PANDER promoter provides 
an excellent mechanism by which the transcriptional regulation 
of PANDER in the liver can be examined. Although the activation 
of the PANDER promoter has been studied in the endocrine 
pancreas and has shown activity within the liver, there have 
been no studies to date that explore the regulation of the 
PANDER promoter in the liver [66, 87]. This study seeks to 
identify the mechanism by which PANDER is regulated in the liver 
and its function in response to activation by secretagogues. 
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This study will prove invaluable in further understanding how 
hepatic PANDER is regulated and determines glycemic levels and 
could further demonstrate that PANDER, under pathological 
conditions, may propagate T2D and represent a future therapeutic 
target.  
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Figure 1: Pathophysiology of T2D. In healthy individuals, the 
pancreas secretes insulin in response to elevated blood glucose. 
In response to insulin, skeletal muscles uptake glucose into the 
cells, the glucose production within the liver is suppressed and 
adipose tissue is prevented from releasing free fatty acids into 
the blood. Under conditions of diabetes, β-cell dysfunction 
causes a partial loss of insulin production. Insulin resistance 
in the tissues results in insulin action not being completed 
within the cells. Both conditions result in an increase in free 
fatty acids and glucose within the blood. Adapted from Stumvoll, 
et. al. (2005) [8]. 
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Figure 2: PANDER β-β-α Fold. Murine PANDER structure above with 
diagram below colored from blue to red from N terminus to C 
terminus. Disulphide topology is indicated by dashed lines. 
Figure from Johansson et. al. (2013) [64] with permissions from 
Elsevier. 
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Figure 3: Increased PANDER levels during fed conditions. Western 
analysis was performed on liver lysates obtained from B6SJLF WT 
and PANTG mice following a 16 hour fast (Top) or 4 hour re-feed 
(Bottom).  Lanes 1-4 on top and bottom western are from WT 
livers, and lanes 5-8 are from PANTG mice. Figure from Robert-
Cooperman et. al. (2014) [70] with permissions from 
BioScientifica Ltd.   
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Figure 4: Stable isotope labeling of amino acids in cell culture 
(SILAC) analysis of PANTG. Relative changes in the levels of 
identified proteins were determined by the ratio of PANTG to 
that of WT and normalized to Tubulin B5. (A) IPA analysis of 
predicted impacted metabolic functions indicates lipid 
metabolism is altered in PANTG liver.  (B) Differentially 
expressed hepatic proteins identified in PANTG and predicted to 
increase triglyceride production. (C) Network analysis of 
differentially expressed proteins that molecularly interact 
involved in triglyceride production. Figure from Robert-
Cooperman et. al. (2014) [70] with permissions from 
BioScientifica Ltd.   
 Discussion
The hallmark characteristics of our PANTG model
in younger male mice demonstrated the following:
1) increased fasting hyperglycemia and insulinemia,
2) impaired glucose tolerance, 3) increased hepatic insulin
resistance, 4) increased proteomic profile of lipogenesis
and gluconeogenesis, 5) increased hepatic triglyceride
content, 6) decreased hepatic glycogen, and 7) decreased
p-AMPK signaling. These findings strongly suggest that
pancreas-specific PANDER can alter glycemic levels
through what appears to be a specific interaction with
the liver and impact phosphorylation of critical down-
stream hepatic signaling molecules such as AMPK. The
generation and evaluation of the pancreas-specific PAN-
DER overexpressing transgenic mouse allowed us to
evaluate the physiologic effects of secreted PANDER and
the impact on glycemic and lipid modulation.
To put our data in the context of other published
in-vivo studies, we compared our results to the overall
findings of others, albeit this comparison was made to
acute models (Table 1). The two other published studies
utilized tail vein-injected adenoviral-delivered PANDER to
induce a hepatic overexpression of PANDER (Wilson et al.
2010, Li et al. 2011). Some of the earliest reports detailing
the localization of PANDER did not find any expression
in the liver (Zhu et al. 2002), but recently others have
surfaced to demonstrate that PANDER is expressed within
this organ as well and is consistent with our findings
(Li et al. 2011, 2013, Mou et al. 2013). Therefore, there is
definitive physiological relevance to this approach but
does not take into account the biological influence of
pancreas-specific PANDER. Both prior studies evaluated
the impact of Ad-PANDER following either 3 (Li et al.
2011) or 7 days (Wilson et al. 2010) post viral
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Figure 5
Stable isotope labeling of amino acids in cell culture (SILAC) analysis of
PANTG. Total protein isolate was pr pared from isolated livers from PANTG
and WT mice (nZ6 per group) obtained uring fed conditions. Following
processing and SILAC an lysis, 1640 proteins were identified and
quantitated. Data were normaliz d and analyzed using the Ingenuity
Pathway Analysis (IPA) program. Relative chang s in the l vels of identified
proteins were determined by the ratio of PANTG to that of WT and
normaliz d to Tubulin B5. (A) IPA analysis of predicted impacted
metabolic functions indicates lipid metabolism is altered in PANTG liver.
(B) Differentially expressed hepatic proteins identified in PANTG and
predicted to increase triglyceride production. (C) Network analysis of
differentially expressed proteins involved in triglyceride production
emonstrated to functionally interact as indicated by lines.
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Figure 4: continued.  
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Figure 5: Metabolic signaling in the liver in response to 
insulin. The insulin signaling cascade is initiated by the 
binding of insulin to the insulin receptor. This binding induces 
IRS proteins to bind to the phosphorylated receptor and are 
subsequently phosphorylated creating docking sites for proteins 
such as IRS-1/2 and phosphoinositide-3 (PI-3) kinase. This 
signal is then transferred onto further molecules such as Akt a 
PKC. The overall action of insulin on the liver is to decrease 
gluconeogenesis and increase glycolysis, glycogen synthesis and 
lipogenesis. Figure adapted from Dr. Burkhardt’s grant proposal. 
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Figure 6: Regulation of ChREBP activity in the nucleus. 
Increased glucose levels cause PP2A activity to dephosphorylate 
ChREBP and facilitate its translocation to the nucleus. Nuclear 
ChREBP dimerizes with Mlx and binds to the promoters of its 
target genes (FAS, ACC, L-PK). This activity is reversed by the 
the activity of PKA and AMPK, activated by glucagon and fatty 
acids, which phosphorylate ChREBP and cause it to be shuttled 
from the nucleus. Adapted from Uyeda, et. al. (2006) [98]. 
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Figure 7: Schematic of Specific Aims. This study characterized 
the expression, regulation and function of PANDER within the 
liver.  
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CHAPTER 2: MATERIALS AND METHODS 
 
 
Note to Reader 
Portions of this chapter have been previously published in 
Molecular and Cellular Endocrinology, 2015, 413: 101-112, and 
have been reproduced with permission from Elsevier. Whitney A. 
Ratliff designed the study, acquired, analyzed and interpreted 
the data and wrote the manuscript. Mark G. Athanason, Alicia C. 
Chechele, Melanie N. Kuehl, Amanda M. Fernandez and Catherine B. 
MarElia assisted with data acquisition. Brant R. Burkhardt 
designed the study, interpreted the data and contributed to 
manuscript writing. All authors read and approved the final 
manuscript. 
 
Identification of Transcriptional Start Site 
The 5’-ends of murine PANDER mRNAs were isolated by 5’ RNA 
Ligase Mediated Rapid Amplification of cDNA Ends (RLM-RACE) 
using the FirstChoice RLM-RACE Kit (Ambion, Austin, TX). Unless 
otherwise noted, all reagents were supplied by the manufacturer. 
The RLM-RACE procedure is outlined in Figure 8. Total RNA was 
isolated separately from the BNLCL2 murine embryonic hepatocyte 
cell line and homogenized murine liver tissue (wild-type B6SJLF) 
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using the RNeasy Mini Kit (Qiagen, Hilden, Germany). All RNA was 
treated with RNAse-free DNAse (Qiagen) to remove any potential 
contaminating genomic DNA. Approximately 10 µg of RNA from the 
BNLCL2 cell line and murine liver tissue were treated by calf 
intestinal phosphatase to remove 5’-phosphates from DNA, rRNA, 
tRNA, and any degraded mRNA. The RNA was then purified by 
phenol–chloroform extraction, and treated with tobacco acid 
pyrophosphatase to remove the cap structure from intact mRNAs. A 
45-base RNA adapter oligonucleotide was then ligated to the 
previously decapped mRNA population using T4 RNA ligase. A 
random primed reverse transcription polymerase chain reaction 
(RT-PCR) was performed using random decamers. Sequences of all 
listed primer pairs used in the subsequent experiments were 
detailed previously [111]. Following the reverse transcription 
reaction, a nested PCR of 35 cycles (94°C–30 s; 60°C–30 s; and 
72°C 30 s) was performed using first round primers that 
contained the 5’ RACE outer adapter specific primer (5’ RACE 
Outer) along with a PANDER specific outer primer (PANDER74R). A 
second round of amplification was performed using 2 µl of the 
first round reaction products under the same conditions with the 
exception of the 5’ RACE inner adapter specific primer (5’ RACE 
Inner) and an inner PANDER specific primer (PanProTR+8TA or 
+491) and the PCR annealing temperature was increased to 62°C. 
The resultant PCR products were subsequently cloned into the 
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pCR2.1 cloning vector (Invitrogen, Carlsbad, CA). Plasmids were 
then sent to the Moffitt Cancer Center Molecular Genomics Core 
(Tampa, FL) for sequencing to identify the precise TSS. 
 
Identification of Putative Transcriptional Factor Binding Sites 
Potential transcriptional binding sites located within the -832 
to -3 (relative to previously identified pancreatic 
transcriptional start site) region of the PANDER promoter were 
identified using the program of MatInspector 8.0 
(http://www.genomatix.com) or visually identified. 
 
Western Analysis of PANDER Expression 
A commercially prepared tissue blot (Zyagen, San Diego, CA) was 
used containing the following murine tissues: Brain (whole), 
stomach (whole), intestine (whole), colon, liver, lung, kidney, 
heart, ovary, skeletal muscle, spleen, testis, thymus, uterus 
(non-pregnant) and placenta (late pregnancy). The blot was 
rehydrated according to manufacturer’s instructions and probed 
for PANDER using the FAM3B M-80 rabbit polyclonal antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:1000 dilution 
in commercial StartBlock™ blocking buffer (Thermo Scientific, 
Waltham, MA). The blot was then incubated in goat anti-rabbit 
secondary antibody (Santa Cruz Biotechnology) at a 1:10,000 
dilution. The blot was developed using ECL Western Blotting 
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Substrate (Pierce, Rockford, IL) and visualized using the LAS 
3000 Intelligent Dark Box (Fujifilm, Stamford, CT). 
 
Construction of the PANDER Promoter Luciferase Constructs 
Initial PANDER/luciferase constructs were created as described 
previously [111]. Further constructs were created utilizing a 
Bacterial Artificial Chromosome (BAC) construct containing 14 kb 
of sequence upstream of the PANDER coding region as a PCR 
template. This BAC was obtained from Dr. Brant Burkhardt and was 
used as the template for all previously created PANDER promoter 
constructs [111]. Various regions of the PANDER promoter 
spanning from 193 bp upstream of the hepatic transcriptional 
start site to 8 bp downstream of the translational start codon 
(+34 relative to the hepatic transcriptional start site) were 
PCR amplified and cloned into the pGL3-basic (Promega, Madison, 
WI) luciferase reporter plasmid. The PCR amplification 
introduced flanking KpnI and MluI sites that were utilized for 
subsequent ligation with T4 DNA ligase (Invitrogen, Carlsbad, 
CA) into the dephosphorylated and restriction digested pGL3-
basic plasmid. Primers utilized for the promoter truncations are 
listed in Table 1. All primers were synthesized by Integrated 
DNA Technologies (Coralville, IA). All PANDER/luciferase 
constructs were confirmed by restriction digestion. Plasmid 
purifications were performed using the QIAprep Spin Miniprep kit 
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(Qiagen, Hilden, Germany) and confirmed via gel electrophoresis. 
All construct locations are relative to the identified hepatic 
transcriptional start site or translational start codon (where 
noted). All utilized promoter constructs are detailed in Figure 
9. 
 
Cell Culture and Transient Transfections 
β-TC3 (murine insulinoma) cells were cultured in complete RPMI-
1640 (11 mmol/l glucose) with 10% heat-inactivated fetal bovine 
serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 
mmol/l l-glutamine at 37 °C, 5% CO2. BNLCL2 (murine embryonic 
hepatocyte), C2C12 (murine myoblast), NIH-3T3 (murine 
fibroblast) and HepG2 (human hepatocellular carcimoma) cells 
were cultured in complete Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with the same reagents listed above. Prior 
to luciferase experiments, transfection efficiency was confirmed 
visually through transfection of the pEGFP-C1 plasmid (Figure 
10). For each transfection, approximately 2x105 cells per well 
were plated in a tissue culture treated 24-well dish (Becton-
Dickinson, Heidelberg, Germany). PANDER/luciferase constructs 
were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA). Transfections of each plasmid were performed in triplicate 
in at least two independent experiments. Two hours post 
transfection, the media was removed and replaced with fresh 
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culture media. Eighteen hours post-transfection, cells were 
washed with PBS and lysed in 100 µl of 1X Glo Lysis Buffer 
(Promega). Luciferase activity of the promoter constructs was 
measured sequentially using the Dual-Luciferase Reporter Assay 
System (Promega). Luciferase activity was measured for 10 s 
after a 2-s delay using a Monolight 3010 luminometer (Analytical 
Luminescence Laboratory, San Diego, CA).  
 
Insulin and Palmitate Stimulation 
To determine whether the murine PANDER promoter was responsive 
to insulin and/or palmitate, BNLCL2 and/or HepG2 cells were 
plated in 24-well tissue culture dish in appropriate media 
(DMEM) containing 10% heat-inactivated fetal bovine serum, 100 
units/ml penicillin, 100 µg/ml streptomycin, and 2 mmol/l l-
glutamine. As described previously, cells were plated at 2x105 
cells per well. After 24 h, media was replaced with glucose-free 
DMEM containing 1% FBS and 2 mmol/11-glutamine in the complete 
absence of penicillin and streptomycin. The FBS was reduced to 
1% to prevent additional nutrients (ie. Insulin or palmitate) 
being introduced into the media. Penicillin and streptomycin 
were not added due to cytotoxic effects when employed in 
conjunction with the transfection reagent of Lipofectamine 2000 
(Invitrogen, Carlsbad, CA). After 4 h, the cells were 
transfected with PANDER/luciferase constructs using 
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Lipofectamine 2000, as described previously. After 2 h, the 
glucose-free media was removed and replaced with appropriate 
media containing various increasing insulin (Humulin R, Eli 
Lilly, Basingstroke, UK) or palmitate (Sigma-Aldrich, St. Louis, 
MO) concentrations. Palmitate was dissolved in 95% ethanol and 
an ethanol-only control was included to account for cell 
toxicity related to ethanol treatment. This ethanol-only control 
contained 0.95% ethanol, the equivalent of the ethanol contained 
in the highest palmitate treatment. Additional combination 
treatment of palmitate and glucose (Fisher Chemicals, 
Pittsburgh, PA) was included as well. The FBS concentration was 
maintained at 1%, and no penicillin/streptomycin was added. 
After addition of the insulin-containing or palmitate-containing 
media, cells were incubated for an additional 18 h and then 
harvested for luciferase expression as described above. Each 
insulin/palmitate condition was evaluated in triplicate from 3 
independent experiments. 
 
Palmitate Stimulation of β-TC3 Cell Line 
PANDER promoter activity was evaluated in the β-TC3 pancreatic 
β-cell line in response to stimulation with palmitate. β-TC3 
cells were cultured and luciferase assays were performed as 
stated above using the -832/-3 PANDER promoter construct. In 
addition, a time course was performed to evaluate relative 
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luciferase levels over time at 6, 12 and 18 hrs post treatment. 
An ethanol-only control was performed to rule out potential 
cytotoxic effects of the ethanol contained within the palmitate 
treatments.  
 
Glucose-Responsive Experiments 
To determine the potential glucose-responsive expression of the 
murine PANDER promoter, the above procedure was followed using 
varying concentrations of glucose. Initial experiments were 
performed using 1% FBS to prevent additional unaccounted glucose 
being introduced into the media from the typical 10% FBS 
concentration which contributes to about 0.5 mM glucose to the 
final glucose concentration. To further abrogate the potential 
effects of residual glucose in 1% FBS, subsequent experiments 
were performed using 0.1% FBS. 
 
RT-PCR 
To assess the levels of hepatic PANDER mRNA under glucose-
stimulation, primary murine hepatocytes (Triangle Research Labs, 
Triangle Park, NC) were plated on a 6-well dish at a 
concentration of 1.2 x 106 cells/well using the Cryopreserved 
Animal Hepatocyte Thawing and Plating Medium provided (Triangle 
Research Labs). The following day, media was removed and 
replaced with fresh media containing 0, 5.5, 11 or 22 mM 
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glucose. After 18 hours, these cells were harvested and RNA was 
extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany), 
all lysates were run through gDNA eliminator spin columns, 
provided in the kit, to remove any genomic DNA contamination. 
RT-PCR was performed according to manufacturer instructions 
using the TaqMan® RNA-to-CT™ 1-Step Kit (Catalog #: 4392653) and 
the Fam3B Gene Expression Assay (Assay ID: Mm00508056_m1) with 
the β-actin Gene Expression Assay as a control (Assay ID: 
Mm00607939_s1) from Life Technologies (Carlsbad, CA). Real Time 
PCR was run using the Applied Biosystems Step One Plus Real Time 
PCR System (Life Technologies, Carlsbad, CA). Relative levels of 
mRNA expression were normalized to β-actin and calculated using 
the 2-ΔΔCT method from 2 independent experiments with each 
condition examined in duplicate.   
 
ChREBP Co-Transfection Experiments 
To determine the potential activation of the PANDER promoter by 
the transcription factor ChREBP, we obtained several expression 
constructs used in previous experiments by Dr. Howard Towle 
(University of Minnesota, Minneapolis, MN) [112-117]. We 
utilized an expression construct for wild-type ChREBP protein as 
well as Mlx, the co-factor shown previously to facilitate ChREBP 
activity [114]. An acetyl co-A carboxylase promoter construct 
was used as a positive control to assess the activity of these 
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expression plasmids (Figure 11) [117]. To assess the effect of 
ChREBP on the PANDER promoter under baseline conditions (10% 
FBS), we followed the original protocol listed above and 
transfected the cells with the -832/-3 PANDER promoter construct 
alone or with the addition of the Mlx construct, the ChREBP 
construct or both.  Additional experiments were performed under 
glucose-stimulatory conditions using the procedure outlined 
above for glucose-stimulation in DMEM containing 1% FBS. 
 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation was performed using the EZ-ChIP 
(Millipore, Darmstadt, Germany) kit. Manufacturer’s instructions 
were followed unless otherwise noted. Cryopreserved primary 
murine hepatocytes (Triangle Research Labs, Research Triangle 
Park, NC) were plated on a 6-well dish at a concentration of 1.2 
x 106 cells/well using the Cryopreserved Animal Hepatocyte 
Thawing and Plating Medium provided (Triangle Research Labs). 
The next day, prior media was removed and replaced with fresh 
media containing 11 or 22 mM glucose. These cells incubated 
overnight and were then fixed with 1% (v/v) fresh formaldehyde 
to cross-link the DNA with any associated transcription factors. 
After 10 mins incubation, 300 µL 10X glycine was added to quench 
the unreacted formaldehyde. The cells were then harvested 
according to manufacturer’s protocol and sonicated using the 
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Bioruptor Plus sonicator (Diagenode, Denville, NJ) for 10 mins 
on HIGH with 30 sec ON/OFF cycles. For immunoprecipitation, the 
following antibodies were added to one of two tubes: 1.0 µg 
normal mouse IgG (Millipore, Darmstadt, Germany) and 10 µg ChIP 
grade rabbit polyclonal anti-ChREBP antibody (Abcam, Cambridge, 
MA).  
 
PCR of Immunoprecipitated Chromatin 
Following the purification of immunoprecipitated chromatin, PCR 
was performed on the samples. Previously designed primers were 
used to amplify portions of the PANDER promoter, including -
293/+25, -193/+25 and -93/+25. Two sets of tubes were prepared 
for PCR. One contained water, Accuprime Supermix II (Invitrogen, 
Carlsbad, CA), appropriate primers and immunoprecipitated DNA. 
The second set contained input DNA in place of the 
immunoprecipitated DNA. All PCR reagents were added to thin-
walled, flat-topped, 0.5 mL PCR tubes (Molecular Bioproducts, 
San Diego, CA). PCR was run in an MJ Research PTC-200 DNA Engine 
thermocycler using the following conditions: 94 °C for 3 min 
(one cycle, for initial denaturation), 94°C for 20 s 
(denaturation)/59 °C for 30 s (annealing)/72°C for 30 s 
(extension) (32 cycles), with one cycle of 72°C for 2 min for 
final extension. Samples were then analyzed on a 1% agarose gel 
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and visualized using the Amersham Imager 600 (GE Healthcare Life 
Sciences, Pittsburgh, PA).  
 
Site-Directed Mutagenesis 
Site directed mutagenesis was performed to create a PANDER 
promoter construct not containing the third E-box element.  The 
PANDER promoter luciferase construct containing the -493/-3 
region of the PANDER promoter was mutated using the Agilent 
QuikChange II Site-Directed Mutagenesis kit (Santa Clara, CA) 
according to manufacturer instructions. A single primer was used 
that encompassed the regions adjacent, but not containing the 6 
nucleotides (CATTTG) that make up the third E-box element. The 
primer used to create the mutant construct is listed in Table 1. 
All primers were synthesized by Integrated DNA Technologies 
(Coralville, IA). Plasmid purifications were performed using the 
QIAprep Spin Miniprep kit (Qiagen, Hilden, Germany) and 
confirmed via gel electrophoresis. The PANDER/luciferase 
construct deletion was confirmed by sequencing at the Moffitt 
Sequencing Core (Tampa, FL). Subsequent luciferase assays were 
performed using the procedures detailed previously for baseline 
activity and glucose-responsiveness.  
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RT-PCR of PANDER Levels in Livers from Non-Obese Diabetic (NOD) 
Mice 
To determine differences in PANDER mRNA levels in a Type I 
Diabetes in vivo model, several NOD mouse livers were provided 
from Dr. Mark Atkinson of the University of Florida. All livers 
were obtained from 28-week-old females housed in compliance with 
the University of Florida Institutional Animal Care and Use 
Committee (IACUC). Blood glucose readings were monitored weekly 
using a FreeStyle Blood Glucose monitoring system (Abbott, 
Abbott Park, IL) to assess the progression of diabetes. Prior to 
sacrifice, 3 of 7 NOD mice were determined to be within the 
diabetic range (consecutive blood glucose readings >200 mg/dL), 
while the remaining 4 were non-diabetic. Livers were obtained 
upon sacrifice and snap-frozen in liquid nitrogen prior to being 
stored at -80°C. Livers were thawed and homogenized using a 
Qiagen TissueRuptor Tissue Disruption Systems and RNA was 
isolated according to manufacturer instructions using the RNeasy 
Mini Kit (Qiagen, Hilden, Germany). RT-PCR was performed on RNA 
samples, as detailed previously, using 500 ng NOD liver RNA per 
sample.  
 
Statistical Analysis 
Data are presented as mean ± S.E.M. Statistical significance of 
differences between groups was analyzed by unpaired Student’s t-
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test or by one-way analysis of variance (ANOVA) when more than 
two groups were compared. 
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Figure 8: RLM-RACE procedure. This scheme outlines the steps in 
the RLM-RACE procedure seeking to identify the transcriptional 
start site of the PANDER promoter. 
RLM-RACE
RNA extraction from desired cells or tissues, treat with DNase
CIP treatment to remove 5’ PO4 from undesired nucleic acids 
(intact mRNA is not altered)
Phenol-Chloroform extraction
TAP treatment to remove 5’ caps from mRNA
Ligation 5’ RACE adapter to 5’ end of decapped mRNA
Reverse transcriptase reaction to obtain cDNA
First round PCR using outer RACE and PANDER primers
Second round PCR using inner RACE and PANDER primers
TA cloning into pCR2.1 vector
Sequencing
PANDER AAAAAAA5’ RACE Adapter
PANDER5’ RACE Adapter
Pander74R
P5’ RACE Adapter
PanProTR+8TA
ATG, Translational start site
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Figure 9: PANDER promoter luciferase constructs. Several PANDER 
promoter constructs were created. Fragments of the PANDER 
promoter were flanked by KpnI and MluI restriction sites to 
allow for cloning into the pGL3-basic luciferase plasmid 
construct. 
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Table 1: List of primers utilized for creation of 
PANDER/luciferase constructs 
 
  
Name Sequence 
Forward/
Reverse 
PanPro+300KpnIF 5'-GCGGTACCCTGTGCAGCCCCACCCAT-3' F 
PanPro+400KpnIF 5'-GCGGTACCTTTTCTGCCTGCCCCAAG-3' F 
PanPro+450KpnIF 5'-GCGGTACCTAGGCCAGCTTTCATAGG-3' F 
PANDERTA+8MluI 5'-GCACGCGTGGACGCATCTTCCAGAAACTGCT-3' R 
PANPRO-1TAMluI 5'-GCACGCGTCTTCCAGAAACTGCTCTCTTTC-3' R 
PanProDelEbox3 5’-CTTTATGGATCCTCCCTGGGAATTGGTCCAC-3’ F 
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Figure 10: Transfection Efficiency of BNLCL2, HepG2, C2C12 and 
NIH-3T3 cell lines. BNLCL2, HepG2, C2C12, and NIH-3T3 cell lines 
were transfected with the pEGFP-C1 plasmid construct and 
evaluated for transfection efficiency via fluorescent 
microscopy.  
 
 
 
 
 
 
 
 
59 
 
 
 
 
Figure 11: Acetyl-CoA Carboxylase promoter luciferase control 
plasmid activity, co-transfected with ChREBP and Mlx expression 
plasmids. ChREBP and Mlx expression plasmid activity was 
confirmed using a ACC promoter luciferase construct. ACC 
promoter is only active when ChREBP and Mlx expression plasmids 
are present. 
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CHAPTER 3: RESULTS 
 
 
Note to Reader 
Portions of this chapter have been previously published in 
Molecular and Cellular Endocrinology, 2015, 413: 101-112, and 
have been reproduced with permission from Elsevier. Whitney A. 
Ratliff designed the study, acquired, analyzed and interpreted 
the data and wrote the manuscript. Mark G. Athanason, Alicia C. 
Chechele, Melanie N. Kuehl, Amanda M. Fernandez and Catherine B. 
MarElia assisted with data acquisition. Brant R. Burkhardt 
designed the study, interpreted the data and contributed to 
manuscript writing. All authors read and approved the final 
manuscript. 
 
Identification of the Murine Hepatic PANDER Transcription Start 
Site 
Earlier experiments evaluating PANDER transcriptional control 
strongly suggested the presence of an additional TSS downstream 
of the one previously identified [118]. To determine the 
presence of a unique hepatic TSS, RLM-RACE was performed on 
total RNA isolated from BNLCL2 murine embryonic hepatocytes and 
murine liver lysate (B6SJLF strain). A robust product of 
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approximately 70 bp was amplified from both of these sources 
following PCR amplification of RLM-RACE obtained template 
(Figure 12A). The PCR products were subsequently cloned and 
sequenced (Moffitt Cancer Center), revealing a newly identified 
single TSS 26 bp upstream of the murine PANDER translational 
start codon. This is in contrast to the previously identified 
transcriptional start site 520 bp upstream of the translational 
start codon that was determined from the pancreatic β-TC3 cell 
line [111]. The region upstream of this newly identified TSS 
contains several potential glucose-responsive binding domains 
including three E-box elements within the -832/-3 region that 
were later investigated for interaction with ChREBP-1 and 
promoter activity (Figure 12B). Figure 12C details the 2 
alternatively spliced mRNA variants of the murine PANDER gene, 
which differ by a truncation of the 5’ end. It is worth nothing 
that the first mRNA is the gene variant investigated in this 
study. There have been no previous studies that have determined 
any expression or function of the second variant. 
 
Cell-Specific Characterization of the PANDER Promoter  
To evaluate if the PANDER promoter was tissue selective with 
regard to the liver specific TSS, we performed reporter gene 
analysis encompassing a broad range of tissue cell lines. 
Several truncations of the PANDER promoter, ranging from -1832 
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to -3 have been previously cloned into the pGL3 luciferase 
vector [111]. Several cell lines were transfected evaluating 
these PANDER promoter plasmids to examine PANDER promoter 
activity with a focus on liver-derived cell lines. Significantly 
higher PANDER promoter mediated expression was revealed in the 
liver-derived cell lines of BNLCL2 murine embryonic hepatocyte 
cell line and the HepG2 human hepatocarcinoma cell line (Figure 
13A). Lowest expression was found in the C2C12 murine myoblast 
cell line and NIH-3T3 murine fibroblast cell lines. Modest 
PANDER expression was observed in the β-TC3 murine insulinoma 
cell line.  Based on the promoter deletion analysis, the regions 
encompassing -832/-3 and -493/-3 demonstrated  the highest 
activity in the BNLCL2 (10.1 and 7.9-fold, respectively) and 
HepG2 (7.1 and 6.9-fold, respectively) cell lines above the 
basic vector with no significant differences between the two 
constructs. To further examine PANDER expression, we performed 
western blot analysis on a survey of murine tissues obtained 
from the C57BL/6J mouse. PANDER was strongly expressed in the 
liver followed by the brain and ovary (Figure 13B). Taken 
together, the PANDER promoter has robust tissue specificity in 
both human and murine liver-derived cell lines and this finding 
appears to drive PANDER protein expression within the liver.   
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Minimal Element of PANDER Promoter 
To identify the minimal element necessary for PANDER activity 
within the liver, progressive deletions of the promoter region 
within the -832/-3 region were utilized followed by subsequent 
transfection into the BNLCL2 cell line. Under basal glucose 
conditions, the -293/-3 region displayed the highest promoter 
activity (17.4-fold) followed by the -393/+491 (13.9-fold), -
493/-393 (4.7-fold), -493/-293 (4.6-fold) and -338/-493 (1.7-
fold) constructs (Figure 14A). Further promoter deletions were 
generated to identify minimal element.  A 100 bp deletion 
between the regions of  -193 to -93 resulted in a major 
abrogation of promoter activity (Figure 14B), with subsequent 
deletions not having any dramatic impact on expression.  
 
Secretagogue-Mediated Expression of the Murine PANDER Promoter 
in BNLCL2 Cells 
PANDER expression has been shown to be induced by glucose in 
pancreatic β-cells (β-TC3), but not in α-cells [111]. Arginine 
and, to a greater extent, insulin have been shown to induce 
PANDER expression in α-cells, but not in β-cells [83].  In 
addition, in-vivo studies performed on the PANDER transgenic 
mouse model have indicated that PANDER expression is increased 
in the liver during fed conditions [70], whereas Li et al. has 
indicated that high fat diet may induce hepatic PANDER 
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expression [67]. These studies suggest that PANDER expression 
may be increased in response to glucose, insulin, and/or fatty 
acids; however, to date, there have not been any definitive 
studies investigating the impact of secretagogues on PANDER 
promoter activity within the liver. To evaluate this activity, 
we transiently transfected BNLCL2 cells with the -832/-3 
construct in the absence or presence of varying concentrations 
of insulin, palmitate and/or glucose and measured promoter 
activity. Both insulin and palmitate were shown to significantly 
decrease PANDER promoter activity (Figures 15A and 15C). 
Combining glucose with palmitate treatment resulted in a slight 
increase in activity over palmitate alone, though the net result 
was still a decrease in activity with respect to no treatment 
(Figure 15D). The most potent stimulatory effect was found with 
glucose. Glucose treatment significantly increased PANDER 
promoter activity at both the 5.5 and 22 mM glucose conditions 
(Figure 17A) without any measurable effect by L-glucose.  
 
Palmitate Stimulation of β-TC3 Cell Line 
In our time course experiment, relative luciferase levels 
increased over time at the 6, 12 and 18 hour time points, 
however, overall trends remained the same. Expression increased 
significantly at the 6 hour time point, but there was no 
significant change between the 12 and 18 hour time points, 
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suggesting that by 12 hours post-treatment, maximal expression 
has been achieved, but remains stable. PANDER promoter activity 
was significantly decreased in response to palmitate in a dose 
dependent manner, dropping approximately 60% from the 0 mM 
treatment to the 0.25 mM treatment (Figure 16A). This did not 
appear to be related to a cytotoxic effect of the ethanol in the 
palmitate treatment, as promoter activity was not significantly 
decreased when the cells were treated with 0.95% ethanol when 
compared to no treatment (normal culture media) (Figure 16B).  
 
Minimal Element for Glucose-Responsiveness of the PANDER 
Promoter 
To precisely map and identify the glucose-responsive regions of 
the PANDER promoter, BNLCL2 cells were transfected with several 
truncated versions (-393 to -3 and -293 to -3) of the PANDER 
promoter constructs and treated with varying concentrations of 
glucose.  In summary, the minimal element was sufficient to 
confer glucose-responsiveness of the PANDER promoter (Figure 
17B). 
 
Glucose-Responsive PANDER mRNA Levels in Primary Hepatocytes 
RT-PCR was performed on isolated RNA from primary hepatocytes 
treated with 0, 5.5, 11 or 22 mM glucose to determine relative 
changes in PANDER levels. This assay revealed a significant 
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dose-dependent increase in PANDER message, with the 11 and 22 mM 
glucose treated groups showing approximately 4 and 9 times the 
levels of the 0 mM group, respectively (Figure 17C). Therefore, 
it appears that the primary hepatocyte mRNA levels of PANDER 
follow the trend demonstrated by promoter activity in the 
luciferase assay. 
 
ChREBP Mediated PANDER Expression 
The expression of many glucose-sensitive genes within the liver 
is determined by the carbohydrate response element binding 
protein (ChREBP) [119]. ChREBP recognizes conserved carbohydrate 
response elements (ChoREs) in numerous gene promoters and 
regulates expression particularly under glucose stimulated 
conditions.  Therefore, this transcription factor was an ideal 
candidate to investigate potential interaction with the PANDER 
promoter. To determine the level of ChREBP mediated PANDER 
promoter activity, initial co-transfection experiments were 
performed. The PANDER promoter construct was co-transfected with 
a ChREBP expression plasmid and an Mlx co-activator expression 
plasmid under increasing glucose conditions and activity was 
evaluated via luciferase assay. Although modest, PANDER promoter 
activity was significantly increased in the presence of both 
ChREBP and Mlx expression plasmids under glucose stimulated and 
unstimulated conditions (Figure 18A).  
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ChREBP Binding to the PANDER Promoter as Determined by Chromatin 
Immunoprecipitation 
To functionally demonstrate that ChREBP is binding directly to 
the PANDER promoter, we performed chromatin immunoprecipitation. 
We selected three truncations of the PANDER promoter based upon 
the potential E-box binding regions located therein: -293/ +25, 
-193/+25 and -93/+25. Following ChREBP immunoprecipitation of 
cross-linked primary murine hepatocyte DNA and subsequent PCR 
amplification with PANDER promoter specific primers, we showed 
robust amplification at the expected molecular weight 
(approximately 218 bp) for the -193/+25 primer pair in the 22 mM 
condition only with no detected ChIP mediated amplification in 
the 11 mM condition (Figure 18B). No amplification was observed 
in the IgG non-specific binding control condition. This region 
(-193/+25) contains one full and one partial E-box element and 
was shown to be the minimal element responsible for baseline 
promoter activity.  
 
E-box 3 Deletion Impairs Basal and Glucose-Stimulated PANDER 
Promoter Activity 
Site Directed Mutagenesis was performed to eliminate the third 
E-box element from the PANDER/luciferase promoter construct. 
This element was the only full E-box element contained within 
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the region identified for ChREBP binding by chromatin 
immunoprecipitation. Following site-directed mutagenesis and 
confirmation by sequencing, E-box 3 deleted PANDER luciferase 
plasmids were transfected into BNLCL2 cells and assayed in 
comparison to the PANDER/luciferase parental construct (-493/-
3). Under basal conditions (5.5 mM glucose), the activity of the 
E-box 3 deletion construct was significantly reduced by 
approximately 60% as compared to the parental construct (Figure 
19A). Glucose-responsiveness was then assessed in the absence of 
E-box 3. The overall activity and the glucose response of the E-
box 3 construct was significantly reduced when compared to the -
493/-3 construct under all conditions (Figure 19B).   
 
Hepatic PANDER Levels are Increased in Diabetic NOD mice 
To further examine the impact of glucose on hepatic PANDER 
expression, we evaluated the T1D model NOD mouse.  This was 
chosen to determine if extremely high glucose concentrations as 
observed in diabetic NOD mice would also stimulate hepatic 
PANDER expression. PANDER levels were examined from livers 
obtained from recent onset diabetic and non-diabetic NOD mice by 
RT-PCR analysis. The average blood glucose levels were 
approximately 386 and 135 mg/dL in the diabetic and non-diabetic 
groups, respectively.   PANDER was significantly elevated in the 
diabetic NOD mice (approximate 7 fold increase) as compared to 
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their non-diabetic counterparts demonstrating that increased 
hepatic PANDER expression may reflect and be directly regulated 
by increased circulating glucose (Figure 20).  
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Figure 12: Identification of the murine hepatic transcriptional 
start site. The hepatic transcriptional start site was 
determined by 5’ RNA ligase mediated rapid amplification of cDNA 
ends (RLM-RACE) using total RNA from murine embryonic 
hepatocytes (BNLCL2) and primary murine liver tissue (B6SJLF). 
(A) RLM-RACE PCR products were analyzed on a 2% agarose gel. The 
resultant products after 2 rounds of nested PCR are shown. Lane 
1 is the product from BNLCL2 cells and Lane 2 is the product 
from murine liver lysate. (B) The DNA sequence from -829 to +29 
is shown. The identified transcriptional start site is bolded 
and denoted by +1 hepatic. The previously identified pancreatic 
start site is denoted by +1 pancreatic. Putative transcription 
factor binding sites as predicted by MatInspector 7.0 
(Genomatix) are shown and underlined. These sites include A and 
E box elements, hepatocyte nuclear factor (HNF), signal 
transducer and activator of transcription (STAT) and octamer 
binding protein-1 (Oct-1). The PANDER translational start codon 
ATG is italicized and located at the end of the nucleotide 
sequence. (C) Schematic of the alternative splice variants of 
the murine PANDER gene. The murine PANDER gene exists as two 
splice variants, differing by a truncation of the 5’ end. The 
first spice variant is the gene investigated in this study. 
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Figure 12: continued. 
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Figure 12: continued.  
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Figure 13: Cell specificity and baseline activity of the murine 
PANDER promoter. (A) PGL3 luciferase reporter plasmid containing 
the -832 to -3 region of the PANDER promoter upstream of the 
luciferase gene was transfected into BNLCL2, HepG2, β-TC3, NIH-
3T3 and C2C12 cells. Luciferase activity was measured following 
transfection under basal glucose conditions and is reported as a 
fold change over the promoterless PGL3-basic plasmid. Normalized 
promoter-less pGL-3 basic plasmid is set at 1. All data are 
shown as mean ±S.E. from 3 independent experiments with each 
PANDER/luciferase construct transfected in triplicate. ** P < 
0.01, *** P < 0.001 as compared to the promoterless plasmid as 
determined by ANOVA. (B) A commercially prepared western blot 
panel containing several murine tissues (Zyagen) was probed for 
murine PANDER. The resultant bands are shown for PANDER positive 
detection.  
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Figure 13: continued.  
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Figure 14: PANDER promoter deletion analysis. (A) pGL-3 
luciferase reporter plasmids containing various truncations (as 
shown) of the PANDER promoter were obtained and transfected into 
BNLCL2 cells. The resultant luciferase activity is shown. (B) 
Several pGL-3 luciferase constructs were created with new 
truncations of the PANDER promoter encompassing the 
translational start codon. To identify the minimal element 
necessary for glucose-responsiveness in the PANDER promoter, 
four luciferase reporter constructs were used containing the -
493/-393, -393/-293, -393/-3 and -293/-3 promoter regions. (A) 
These constructs were transfected into BNLCL2 cells and treated 
with 0 mM, 5.5 mM or 22 mM glucose, as described previously. 
Luciferase activity was measured after 18 h and is reported as a 
fold change from the 0 mM condition. Normalized 0 mM condition 
is set at 1. All data are shown as mean ±S.E. from 2 independent 
experiments with each PANDER/luciferase construct transfected in 
triplicate. These constructs were transfected into BNLCL2 cells. 
Resultant luciferase activity is shown. ** and  *** denotes a P-
value < 0.01 and  < 0.001, respectively, when compared to the 
promoterless plasmid. luciferase activity is shown. ** and  *** 
denotes a P-value < 0.01 and  < 0.001, respectively, when 
compared to the promoterless plasmid. 
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Figure 14: continued.  
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Figure 15: Insulin and palmitate inhibit PANDER promoter 
activity. The -832/-3 PANDER promoter construct was used to 
determine the level of stimulation of the promoter in response 
to several secretagogues. (A) HepG2 cells and (B) BNLCL2 cells 
were transfected with the PANDER promoter construct. After 2 h 
media containing various concentrations of insulin was applied. 
Luciferase activity was measured after 18 h and is reported as a 
fold change from the 0 mM condition. Normalized 0 mM condition 
is set at 1. All data are shown as mean ±S.E. from 2 independent 
experiments with each PANDER/luciferase construct transfected in 
triplicate. (C) BNLCL2 cells were transfected with the PANDER 
promoter construct and treated with media containing various 
concentrations of palmitate alone or palmitate with glucose (D) 
after 2 h. Luciferase activity after 18 h is shown as a fold 
change from the 0 mM condition. The asterisk denotes a p-value 
of less than 0.05 when compared to the untreated condition. 
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Figure 15: continued.  
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Figure 15: continued. 
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Figure 16: Palmitate Stimulation of β-TC3 cell line.(A) β-TC3 
cells were treated with 0, 0.25, 0.5 and 1 mM palmitate and 
luciferase assay was performed at 6, 12 and 18 hours post-
treatment. *** represents a p-value of <0.001 compared to the 1 
mM treatment. # represents a p-value of <0.05 between the 0.25 
and 1 mM treatment groups. & represents a p-value of <0.05 
between 0.25 and 0.5 mM treatment groups. (B) β-TC3 cells were 
treated with 0.95% ethanol or normal culture medium following 
transfection with a PANDER promoter construct and a luciferase 
assay was performed. 
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Figure 16: continued. 
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Figure 17: Glucose-responsiveness of the PANDER promoter. 
Glucose responsiveness of the PANDER promoter was assessed in 
the -832/-3 construct. (A) This construct was transfected into 
BNLCL2 cells and treated with 0 mM, 5.5 mM or 22 mM glucose, as 
described previously. (B) To identify the minimal element 
necessary for glucose-responsiveness in the PANDER promoter, two 
luciferase reporter constructs were used containing the -393/-3 
and -293/-3 promoter regions. Luciferase activity was measured 
after 18 h and is reported as a fold change from the 0 mM 
condition. Normalized 0 mM condition is set at 1. All data are 
shown as mean ±S.E. from 2 independent experiments with each 
PANDER/luciferase construct transfected in triplicate. The 
asterisk denotes a p-value of less than 0.05 when compared to 
the untreated condition. (C) Relative PANDER mRNA levels were 
determined in primary hepatocytes treated with 0 mM, 5.5 mM, 11 
mM or 22 mM glucose. Relative -ΔΔCt values are reported as a 
fold change above the 0 mM condition. All data are shown as mean 
±S.E. from 2 independent experiments. *** P < 0.001 from 0 mM 
glucose condition, # P < 0.05 from 5.5 mM condition and & P < 
0.05 from 11 mM condition. 
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Figure 17: continued. 
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Figure 17: continued.  
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Figure 18: ChREBP mediated activity of the PANDER promoter. (A) 
Co-transfection experiments were performed to determine the 
effect of increased carbohydrate responsive element binding 
protein (ChREBP) on PANDER promoter activity. BNLCL2 cells were 
transfected with either the -832/-3 PANDER promoter construct 
alone or in combination with the wild-type ChREBP expression 
plasmid along with the Mlx coactivator expression plasmid and 
stimulated with 0 mM, 5.5 mM or 22 mM glucose. Luciferase 
activity after 18 h is reported as fold change over the PANDER 
promoter All data are shown as mean ±S.E. only condition. 
Normalized promoter only condition is set at 1. from 2 
independent experiments with each PANDER/luciferase construct 
transfected in triplicate. The asterisk denotes a p-value of 
less than 0.05 when compared to the promoter only condition. (B) 
Chromatin immunoprecipitation was performed on crosslinked DNA 
obtained from primary murine hepatocytes treated with 11 mM or 
22 mM glucose to determine binding of ChREBP to the PANDER 
promoter. The representative PCR results using primers specific 
to the -193/+25 region of the PANDER promoter following ChIP 
purification on a 1% agarose gel are shown.  
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Figure 18: continued. 
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Figure 19: E-box 3 deletion decreases basal and glucose 
stimulated PANDER promoter activity. The third E-box element was 
removed via site-directed mutagenesis from the parental (-493/-
3) PANDER/luciferase plasmid. (A) Baseline activity of the 
PANDER promoter under basal cell culture conditions of 5.5 mM 
glucose was assessed in BNLCL2 cells. Data is presented as 
percentage of the -493/-3 PANDER/luciferase activity. (B) BNLCL2 
cells were treated with 0 mM, 5.5 mM, 11 mM or 22 mM glucose 
after transfection with either the -493/-3 PANDER/luciferase 
plasmid or the E-box 3 deleted construct. Data is presented as 
the fold change in relative activity from the -493/-3 
PANDER/luciferase plasmid in the 0 mM condition. Luciferase 
activity was measured after 18 hours. All data are shown as mean 
±S.E. from 2 independent experiments with each transfection 
performed in triplicate. *** P < 0.001 from 0 mM condition and # 
P < 0.05 from 5.5 mM condition. 
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Figure 19: continued. 
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Figure 19: continued.  
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Figure 20: Hepatic PANDER levels in diabetic and non-diabetic 
NOD mice. RT-PCR was performed on livers obtained from 28-week-
old female NOD mice. Glucose concentration (left y-axis) and 
relative PANDER levels (right y-axis) are presented for diabetic 
and non-diabetic NOD mice. RT-PCR PANDER expression levels were 
normalized to non-diabetic NOD mice.  All data are shown as mean 
± S.E. *** P < 0.001 and * P < 0.05.  
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CHAPTER 4: DISCUSSION 
 
 
Note to Reader 
Portions of this chapter have been previously published in 
Molecular and Cellular Endocrinology, 2015, 413: 101-112, and 
have been reproduced with permission from Elsevier. Whitney A. 
Ratliff designed the study, acquired, analyzed and interpreted 
the data and wrote the manuscript. Mark G. Athanason, Alicia C. 
Chechele, Melanie N. Kuehl, Amanda M. Fernandez and Catherine B. 
MarElia assisted with data acquisition. Brant R. Burkhardt 
designed the study, interpreted the data and contributed to 
manuscript writing. All authors read and approved the final 
manuscript. 
 
This study provides the first in-depth analysis of the activity 
and regulation of the PANDER promoter specifically within the 
liver. Our findings have demonstrated that PANDER protein is 
robustly expressed in liver tissue and this is driven by the 
cell type specific activity of the PANDER promoter with glucose 
being the most potent secretagogue. Taken together, our data is 
highly supportive of prior in-vivo studies examining the 
biological function of PANDER in various murine models. For 
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example, Li et al. demonstrated that PANDER mRNA and protein 
levels were increased in the livers of db/db mice as compared 
with db/m mice. Their findings also showed that PANDER protein 
expression was increased in the livers of mice fed a high fat 
diet for 12 weeks. Physical exercise attenuated hepatic PANDER 
expression. Similarly, increased hepatic PANDER expression in 
the livers of HFD-fed rats was also reversed by physical 
exercise, concomitant with an amelioration of fatty liver [67]. 
In addition, our findings support the recent analysis of the 
PANDER transgenic model whereby hepatic PANDER protein levels 
were found to be increased in the post-prandial state in both 
wild-type and PANTG mice [70]. Our studies suggest that the 
increase in PANDER expression may be more due to the 
hyperglycemic state of the previously mentioned models more so 
than increased systemic lipidemia or insulinemia.   
 
In addition, our reported findings are in strong concordance to 
that observed with PANDER expression in the endocrine pancreas.   
Previous studies have shown that the PANDER promoter is highly 
glucose-responsive within the pancreas and that this is due, in 
part, to regulation by the pancreas-specific transcription 
factor Pancreatic Duodenal Homeobox-1 (PDX-1) [111, 118]. Our 
characterization of a novel liver-specific transcriptional start 
site suggests that transcriptional regulation of the PANDER 
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promoter within the liver is under a different TF-mediated 
mechanism as that found for expression from the endocrine 
pancreas, despite both being glucose-responsive. There are many 
genes that are regulated by multiple transcriptional start 
sites. In fact, it is estimated that approximately 35% of genes 
annotated by GENCODE possess more than one start site [120]. 
Data suggest that these start sites are regulated differently 
depending on their position relative to the gene. One study 
found that transcription start sites that are located far 
downstream are more responsive to transcription factors, whereas 
upstream start sites may be regulated more by chromatin 
organization and other factors [121]. Another major determinant 
of alternative transcription start sites is with regard to cell 
type specificity.  Caninci et al. described that mammalian 
promoters can be separated into two classes: (1) conserved TATA 
box–enriched promoters that contain a defined site of TSS and  
(2) more plastic, broad and evolvable CpG-rich promoters [122]. 
Their quantitative analysis of promoter usage in different 
tissues demonstrated that differentially regulated alternative 
TSSs are a common feature in protein-coding genes. Other 
investigators have also demonstrated via large scale TSS 
analysis that promoters do not always initiate transcription at 
a single defined location of base pairs but rather at multiple 
start sites located across a broad region [123]. The PANDER 
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promoter does lack a TATA box and therefore may fall into the 
category of promoters that may contain alternative TSS that are 
regulated by different mechanisms depending on the tissue and 
secretogues of activation.  
 
ChREBP serves a critical role in hepatic de novo lipogenesis and 
potentially the onset of T2D and metabolic syndrome [124]. 
ChREBP appears to regulate approximately 50% of the genes 
critical for hepatic lipogenesis [125]. Potentially acting in 
concert with PANDER, ChREBP may be synergistically both 
promoting and enhancing the PANDER induced hepatic lipogenesis 
observed in PANDER overexpressing animal models [67, 70]. Our 
recent characterization of our PANTG murine model revealed that 
PANDER does globally activate hepatic lipid metabolism. A 
comprehensive proteomic analysis of livers obtained from PANTG 
mice utilizing stable isotope labeling of amino acids in cell 
culture (SILAC) was performed.  This quantitative proteomic 
strategy metabolically labels the entire proteome and allows for 
identification and network elucidation by mass spectrometry 
analysis followed computational determination of differentially 
expressed proteins and networks.  Of the approximately 1600 
proteins identified and quantitated, the differentially 
expressed proteins found in the PANTG revealed that lipid 
metabolism was the top associated network that was significantly 
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increased.  Computational analysis predicted an increased 
quantity of triacylglycerol.  Taken together, we find that both 
ChREBP and PANDER may be working together to comprehensively 
impact hepatic lipogenesis. In addition, ChREBP knockout 
phenotypes may potentially be attributed to the absence of 
PANDER as well.   
   
In addition, ChREBP may be directly involved with the onset or 
progression of type 2 diabetes in a manner similar to that 
reported for PANDER [95, 105, 126]. Expression of ChREBP is 
increased in the liver of adolescents with glucose intolerance 
or T2D [127]. Furthermore, hepatic ChREBP levels are increased 
in obese as compared to lean subjects [128]. In a consistent 
manner to ChREBP, during pathological conditions (ie. 
Hyperglycemia or insulinemia), several review articles have 
detailed that PANDER may impact both T2D and nonalcoholic fatty 
liver disease by inducing selective hepatic insulin resistance 
[107, 129]. A single report has revealed that PANDER circulating 
levels are increased in subjects with T2D [130]. Overexpression 
of PANDER (systemically or liver-specific) results in a 
disruption of insulin signaling with observed decreased 
phosphorylation of protein kinase B (PKB/Akt) resulting in 
hepatic insulin resistance [70]. Concordantly, the absence of 
PANDER as observed in multiple PANDER knockout models, results 
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in enhanced hepatic insulin sensitivity [71, 77]. In a similar 
fashion, knockdown expression of ChREBP in ob/ob mice improves 
glucose tolerance and fatty liver [131].  Therefore, the 
compilation of data surrounding both PANDER and ChREBP is very 
consistent in terms of both serving a role in potentially 
impacting the onset or progression of T2D.  
   
As mentioned previously, the transcriptional regulation of 
PANDER in the liver and endocrine pancreas may have distinct 
mechanisms but there may also be some degree of potential 
overlap with both tissues in regard to ChREBP.  ChREBP is also 
highly expressed in pancreatic islets and appears to be required 
for glucose-stimulated pancreatic β-cell proliferation [132].  
Pancreatic islets obtained from PANDER knockout mice exhibit 
impaired glucose stimulated insulin secretion and calcium 
signaling. Neither islet architecture nor insulin content is 
affected. Although not precisely examined in this study, ChREBP 
may still be interacting with the PANDER promoter within 
pancreatic β-cells and also serve as both a facilitator and 
regulator of PANDER function in this cell type. However, ChREBP 
over-expression in either MIN6 β-cells or pancreatic islets 
decreased PDX-1 gene expression at high glucose concentrations 
[133].  At low glucose, ChREBP inactivation increases PDX-1 
expression. Prior studies regarding the PANDER promoter examined 
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within pancreatic β-cell lines revealed that PDX-1 interacts 
with the various A-box elements within this genomic region and 
facilitates glucose responsive gene expression [118].  
Therefore, based on this evidence, we would speculate that 
ChREBP promotes PANDER expression in pancreatic β-cells.  
Nonetheless, future studies will have to be performed to 
accurately determine how ChREBP mediates PANDER expression in 
the endocrine pancreas.   
 
Much of the research surrounding the investigation of PANDER has 
been associated with T2D [107, 129, 130].  Little has been done 
determining whether PANDER’s impact or hepatic expression may be 
altered by type 1 diabetes (T1D). This presented study has 
initially indicated that glucose serves as a potent secretagogue 
of hepatic expressed PANDER. The NOD model spontaneously 
develops T1D and will display higher glucose levels in 
progressively decreasing insulin concentrations due to 
autoimmune mediated pancreatic β-cell death.  We revealed that 
diabetic NOD mice display increased hepatic PANDER as compared 
to non-diabetic matched NOD controls. This indicates that 
hepatic PANDER expression may be coupled with decreased glycemic 
regulation as determined by hyperglycemic conditions or 
reflective of increased pancreatic and systemic inflammation as 
observed in T1D.  Xu et al. demonstrated that Th1 cytokines such 
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as IFN-γ are potent stimulators of PANDER expression from 
pancreatic cell lines and islets [81]. Concordantly, Th1 
cytokines have been demonstrated to accelerate T1D autoimmunity 
[134, 135]. Therefore, increased circulating glucose and 
cytokine levels as found with T1D conditions may be promoting 
hepatic PANDER expression and further exacerbating hyperglycemia 
by also promoting hepatic insulin resistance.  Numerous animal 
models have indicated that PANDER can promote hepatic insulin 
resistance and lipogenesis [67, 70]. However, further studies 
are needed to fully delineate glucose from cytokine mediated 
hepatic PANDER expression but nonetheless provide some evidence 
that PANDER may be affecting the onset and progression of both 
T1D and T2D.       
 
Elucidating the mechanism of PANDER regulation in several 
tissues may potentially provide further insight into 
understanding the pathology of glucose intolerance, NAFLD and 
T2D.  Our investigation of the PANDER promoter in the context of 
expression within the liver has revealed: (1) the critical 
genetic elements of transcriptional regulation, (2) 
secretagogues mediating expression, and (3) transcription factor 
regulating glucose responsive expression (ChREBP). In 
combination, this information can provide essential insight into 
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the highly complex molecular mechanisms within hepatic metabolic 
regulation [136]. 
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CHAPTER 5: PANDER INDUCED TRANSCRIPTION FACTOR PROFILING 
 
 
Introduction 
While previous aims have focused primarily on the 
transcriptional regulation of PANDER within the liver, our next 
aim was to investigate changes in transcription factor networks 
within hepatocytes in response to treatment with the same 
secreted PANDER from which the crystal structure was elucidated 
by AstraZeneca [64]. A transcription factor array was utilized 
to evaluate levels of 345 transcription factors in untreated and 
PANDER treated primary hepatocytes. Such a study has never been 
performed and will provide invaluable information regarding how 
PANDER may be influencing the transcriptional regulation of 
downstream genes within the liver. PANDER has been studied 
almost exclusively with respect to its function as a modulator 
of metabolic signaling; this study will provide a foundation for 
the investigation of PANDER within a multitude of pathways and 
disease states. 
 
Methods 
Primary hepatocyte culture and treatment. To evaluate the 
response of transcription factor networks in the presence of 
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elevated levels of PANDER protein, primary murine hepatocytes 
(Triangle Research Labs, Triangle Park, NC) were plated on a 6-
well dish at a concentration of 1.2 x 106 cells/well using the 
Cryopreserved Animal Hepatocyte Thawing and Plating Medium 
provided. The following day, media was removed and replaced with 
fresh media containing no treatment or 10 nM PANDER 
(AstraZeneca, Södartälje, Sweden). PANDER protein obtained from 
AstraZeneca was the same isolated secreted PANDER protein used 
in determining the PANDER crystal structure [64]. After 18 h, 
cells were removed from culture for nuclear extraction using the 
Panomics Nuclear Extraction Kit (Panomics, Fremont, CA) 
according to manufacturer’s instructions. One full 6-well plate 
was harvested per treatment group and combined. Following 
extraction, protein concentrations were determined using the 
Pierce 660 nm Protein Assay Reagent (Pierce, Rockford, IL).  
 
Transcription factor protein/DNA Array. To assess the 
transcription factor response to treatment with PANDER or 
insulin, the Panomics Protein/DNA Combo Array was used 
(Affymetrix, Santa Clara, CA). An overview of the principals of 
this assay is included in Figure 21. Nuclear extracts are mixed 
with biotinylated oligonucleotide probes, resulting in 
DNA/protein complexes for those transcription factors present 
within the nucleus at the time of extraction. A column-based 
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system is used to remove unbound probe and elute the DNA/protein 
complexes. The samples are then denatured to liberate the free 
probe. These probes are then hybridized to membranes spotted 
with the consensus binding sequences of 345 transcription 
factors (map shown in Figure 22). After the hybridization step, 
the membranes were developed using ECL Western Blotting 
Substrate (Pierce, Rockford, IL). The membranes were visualized 
using the Amersham Imager 600 (General Electric Healthcare Life 
Sciences, Pittsburgh, PA).  
 
Data analysis for TF Array. Relative densitometry analysis was 
performed on each blot using the ImageQuant TL Version 8.1 
analysis software (General Electric Healthcare Life Sciences, 
Pittsburgh, PA). The identified differentially regulated 
proteins were assigned fold change values from the untreated 
condition, in cases where the untreated condition’s densitometry 
value was 0, the lowest detected densitometry value was 
assigned. The data was then analyzed using the Ingenuity Pathway 
Analysis (IPA) program to evaluate canonical pathways. 
 
Western analysis of PANDER in cell lines. This western blot was 
prepared in collaboration with Punashi Dutta of Dr. Meera 
Nanjundan’s laboratory, according to the Nanjundan lab’s 
protocols using antibody provided by our lab. Protein was 
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harvested from several cancerous and noncancerous cell lines; 
cells were lysed for 1 hour in the appropriate volume of lysis 
buffer containing 150 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 50 mM 
HEPES, 1% Triton X-100, 10% glycerol and protease inhibitor 
tablet (Roche, Madison, WI) in Nanopure water. Cells were 
collected and centrifuged at 14,000 rpm for 10 minutes at 4°C. 
The Bicinchoninic Assay (BCA) Kit (Pierce, Pittsburgh, PA) was 
used to assess protein concentration of the supernatant. Protein 
concentration was normalized to the lowest concentrated sample 
and diluted in lysis buffer. To prepare the samples for loading, 
10 ml 6X SDS dye was added to 50 ml sample and 20 ml was loaded 
into each well on a 12% SDS-PAGE gel. The gel was run for 2 
hours at 100 Volts and then transferred to a PVDF membrane using 
a semi-dry transfer apparatus (Bio-Rad, Hercules, CA) at 0.11 
Amps (or 0.15 Amps for 2 gels) for 2 hours. The membranes were 
washed for 10 minutes in TBST (Bio-Rad, Hercules, CA) on an 
orbital shaker (Thermo Scientific, Hudson, New Hampshire). 
Membranes were then blocked for 1 hour in 5% milk in TBST. Next, 
the blots were rinsed in TBST and probed for PANDER using the 
FAM3B M-80 rabbit polyclonal antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA) at a 1:1000 dilution in commercial StartBlock™ 
blocking buffer (Thermo Scientific, Waltham, MA) and incubated 
overnight on an orbital shaker at 4°C. The following day, the 
membranes were washed 4 times for 15 mins each in TBST. 
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Following the wash a secondary antibody was applied (goat anti-
rabbit (#107-5046, Immun-Star, Biorad, Hercules, CA) at a 
1:10,000 dilution. After the 1 hour secondary antibody 
incubation, the blots were washed 6 times for 15 mins in TBST. 
The blots were developed using enhanced chemiluminescence 
solution (Immun-Star, Bio-Rad) followed by exposure of the 
membrane to X-ray film [137]. Densitometry analysis was 
performed on the ovarian cell lines using ImageJ software 
(National Institutes of Health, Bethesda, MD). 
 
Results 
Identification of differentially expressed transcription factors 
in response to PANDER treatment. Densitometry analysis was 
performed on the untreated and PANDER treated transcription 
factor array membranes (Figure 23). In total, 63 differentially 
regulated transcription factors were identified; 55 were 
upregulated in the PANDER treated condition when compared to 
untreated and 8 were downregulated. A complete list of the 
identified factors and their fold change from the untreated 
condition is shown in Table 2. Of the proteins that were 
contained within the Uniprot database, the top 10 upregulated 
were as follows: GATA-2 [138], CEBPA [139], TCF3 [140, 141], 
PAX6 [142], SP1 [143], YBX1 [144], SAA1 [145], YY1 [146], PAX8 
[147], USF1 [148]. The top 4 downregulated transcription factors 
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were: TEAD1 [149], MYC [150], THRA [151], TNNC1 [152]. Table 3 
details these 14 factors along with their potential roles in 
disease and/or biological functions. Interestingly, several of 
these proteins have been identified as having roles in 
development and cancer or as factors associated with 
proliferation in hepatocytes. 
 
IPA analysis of differentially regulated proteins. 
Differentially regulated proteins were analyzed using the 
Ingenuity Pathway Analysis (IPA) program to elucidate trends and 
identify canonical functions. As expected given the functions of 
the most highly differentially regulated transcription factors, 
the top disease states identified were developmental disorders 
and cancer (Table 4). Gene expression, cellular growth and 
proliferation, cell death and survival, cellular development and 
cell cycle were all identified as the top molecular and cellular 
functions (Table 5), further supporting the potential roles of 
these factors in development and cancer. Among physiological 
system development, hematological and embryonic development were 
identified, as well as several other developmental functions 
(Table 6). Looking specifically within the liver functions, 
there are several proteins, which have been associated with 
hepatotoxicity, including: proliferation, cell death and 
hyperplasia (Figure 24). The top network identified by IPA was 
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that of gene expression, cellular development and embryonic 
development (Table 7). Figure 25 details the interactions of 
differentially regulated transcription factors within this 
network. Taken together, our IPA analysis strongly suggests a 
potential role of PANDER within development and cancer.  
 
PANDER expression in cell lines. To further investigate PANDER’s 
potential role in cancer, several cell lines were evaluated for 
PANDER protein expression via western blot. This blot is shown 
in Figure 26A. Interestingly, we see expression of PANDER in all 
investigated cell lines including: lung, ovarian, breast, 
pancreatic and bone. PANDER has not been studied with respect to 
these tissue types, with the exception of pancreatic, although 
PANDER was identified in the ovary in the tissue blot shown in 
Figure 13B. The ovarian cell lines are of particular interest 
because they include both noncancerous and cancerous cell lines. 
Densitometry analysis reveals that the relative expression of 
PANDER in all cancerous cell lines is decreased when compared to 
the noncancerous ovarian cell line (T80) (Figure 26B). This 
study provides supportive evidence suggesting that PANDER may 
play a role in suppressing the development or progression of 
ovarian and other cancers. 
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Discussion 
Significance of this study. This study provides the first 
analysis of a transcription factor profile in hepatocytes 
following treatment with pure secreted PANDER. Previous studies 
investigating PANDER stimulation have utilized either 
recombinant PANDER protein treatment or overexpression using an 
Ad-PANDER vector [72, 76], which could include both cleaved and 
uncleaved PANDER. This is the first study to use the pure 
secreted (cleaved) PANDER protein used to identify the crystal 
structure [64]. Given that PANDER is secreted from the pancreas 
and binds to its putative receptor on the liver cell membrane 
[84], it stands to reason that treatment of hepatocytes with 
secreted PANDER would provide the most biologically relevant 
snapshot of PANDER’s functional effect on transcription factor 
activity. As such, the differentially regulated transcription 
factors identified in this study provide a unique and broad-
based view into the potential functions of PANDER outside of its 
highly studied effects on metabolic signaling. In particular, we 
have identified a prospective role of PANDER in both cancer and 
development. The relationship between insulin resistance and 
cancer and PANDER’s role in insulin resistance provide support 
for PANDER’s function in cancer development and progression. 
PANDER’s role in development has not been studied, although one 
array study identified FAM3B as being expressed in the 
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endometrium of women recently implanted with an embryo and was 
dysregulated in women with unexplained infertility [153]. This 
study underscores the real need for further study of PANDER with 
respect to both cancer and embryonic development. 
 
Canonical networks effected by PANDER treatment. Ingenuity 
Pathway Analysis identified several of the differentially 
regulated transcription factors associate with PANDER treatment 
as being involved with the gene expression, cellular development 
and embryonic development network (Figure 25). Many of the 
identified transcription factors play central roles within this 
network. CCAAT/enhancer-binding protein (CEBP) was the second 
most highly upregulated transcription factor in the PANDER 
treated hepatocytes and is highly involved with several other 
proteins within this network. CEBP is a transcription factor 
that has been implicated as both a tumor suppressor and a tumor 
promoter under different conditions in several cancers, due to 
its control of proliferative arrest and differentiation [154]. 
CEBP has also been identified as a regulator of the 
transcription of PEPCK [139, 155-157]. PEPCK is a gluconeogenic 
protein that has been previously shown to be upregulated in the 
PANDER transgenic overexpressor mouse [70] and downreguated in 
the PANDER knockout mouse [106]. This recent data regarding the 
upregulation of CEBP in response to PANDER treatment suggests 
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that PANDER may be having an effect on PEPCK levels through a 
CEBP-dependent mechanism, and not solely through a regulation of 
insulin signaling. CEBP also plays an important role in 
proliferation arrest and differentiation of hepatocytes [158], 
as well as lipogenesis through regulation of SREBP-1c [159]. One 
of the most highly downregulated transcription factors in 
response to PANDER treatment was TEAD1 (TEF-1), which also plays 
a central role in the IPA identified top network, interacting 
with SP1, TNNC1, TBP and Smad2/3. TEAD1 is a part of the Hippo 
signaling pathway, which is associated with organ size control 
and tumor suppression through apoptosis [160]. In contrast, 
TEAD1 itself has been implicated as a biomarker for poor 
prognosis in prostate cancer [161] and as an activator of viral 
oncogenes [149, 162]. The downregulation of this protein in 
association with PANDER treatment further supports our initial 
data that suggest that PANDER may play a suppressive role in 
cancer. While there has been little direct research into 
PANDER’s role in cancer, previous studies on PANDER’s role in 
insulin resistance and apoptosis may provide insight into 
potential mechanisms. 
 
Insulin resistance and cancer. Insulin resistance is 
characterized by the body’s reduced ability to respond to 
insulin and suppress hepatic glucose production and stimulate 
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glucose elimination [163]. As a result, blood glucose levels 
rise and, as part of a compensatory mechanism, insulin secretion 
increases to normalize glucose levels. This process leads to a 
hallmark of insulin resistance: hyperinsulinemia. Insulin 
resistance coincides with a number of conditions associated with 
an elevated risk of cancer, including obesity [164], central 
body fat distribution [165], physical inactivity [166], Type 2 
diabetes [167], and hyperglycemia [168]. In addition, there has 
been extensive research linking characteristics associated with 
insulin resistance (in the absence of another concurrent 
disease) to the development and progression of cancer. Previous 
studies have shown that in rats treated with azoxymethane (a 
potent inducer of colon cancer) tumorigenesis was significantly 
enhanced by injection of insulin [169, 170]. Conversely, calorie 
restriction, an effective means to reduce insulin resistance, 
was shown to diminish the development of aberrant foci in the 
colon of these rats [171]. In human epidemiological studies, 
there has been a positive association identified between levels 
of insulin and/or c-peptide, both of which are measures of 
insulin resistance, and occurrence of pancreatic cancer [172, 
173]. The mechanism by which insulin resistance and 
hyperinsulinemia promote cancer is not well understood, however, 
the downstream targets of the insulin signaling pathway reveal 
potential clues as to how insulin may be supporting cancer 
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development. Insulin binding to the insulin receptor in the cell 
membrane activates two major pathways: MAPK and PI3K signaling 
pathways (Figure 27) [163]. The MAPK signaling pathway is 
involved in promoting cell survival and growth. PI3K signaling 
activates Akt, which, in turn, promotes cell proliferation and 
inhibits apoptosis and cell cycle arrest [163]. Both of these 
pathways are promoting cellular behaviors that are 
characteristic of cancer cells. Therefore, the hyperinsulinemia 
associated with the insulin resistant state may be promoting the 
development and progression of cancer though it’s activation of 
the MAPK and PI3K pathways. 
 
PANDER and insulin resistance. PANDER is localized to the 
insulin granules in β cells, suggesting that it may be 
cosecreted with insulin. Pancreatic β cell lines treated with 
glucose saw marked increases in both PANDER and insulin in a 
dose and time dependent manner [82]. In addition, chronic 
hyperglycemia associated with insulin resistance may activate 
PANDER expression and stimulate its cosecretion with insulin in 
pancreatic β cells [107]. PANDER also has marked effects on the 
downstream targets of the insulin signaling pathway. PANDER has 
been shown to inhibit the insulin-stimulated activation of the 
PI3K pathway, including directly inhibiting the phosphorylation 
and subsequent activation of Akt (Figure 27) [84]. By inhibiting 
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Akt, PANDER is effectively increasing the cell’s ability to 
arrest the cell cycle and undergo apoptosis and decreasing cell 
proliferation. This suggests that PANDER may be inhibiting the 
cell’s ability to undergo a transformation into a cancer cell. 
The MAPK signaling pathway, which induces cell growth and 
survival, has been shown to inhibit glucose-induced expression 
of PANDER. This indicates that, when hyperinsulinemia induces 
increased cell survival and growth through MAPK signaling, 
PANDER is subsequently decreased. This decrease in PANDER would 
then cause there to be a further increase in cell proliferation 
and anti-apoptotic effects though it’s inability to inhibit Akt. 
This would suggest that the downregulation of PANDER may be 
necessary for the development of a cancerous phenotype, 
particularly in the insulin-resistant and hyperinsulinemic 
states. 
 
PANDER and p21.  
In addition to its role in the insulin signaling pathway, PANDER 
has been shown to induce apoptosis in primary pancreatic islet 
and islet cell lines. A study seeking to elucidate the mechanism 
behind this response showed that treatment with PANDER resulted 
in a significant downregulation of p21 in murine islets, 
eventually leading to cell death [76]. Cyclin-dependent kinase 
inhibitor 1A (p21) is a cell cycle regulator and an important 
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mediator of tumor suppressor p53 [174, 175]. Several studies 
have demonstrated that p21 expression can have an effect on the 
development and progression of cancer; however, the exact nature 
of this effect has varied. The function of p21 as a checkpoint 
protein suggests that it may have a proapoptotic (and anti-
cancer) nature; several studies have supported this notion [176-
179]. Despite this, new studies suggest that p21 can be found at 
increased levels in tumors and metastases and that p21 
deficiency can protect p53 mutant mice from developing tumors 
[180-183]. While the exact nature of PANDER and p21’s 
interaction is unknown it is reasonable to surmise, given p21’s 
potential role in both cancer development and in cancer 
suppression, that PANDER may also have some role in cancer as 
well.  
 
PANDER and cancer. Given PANDER’s ability to inhibit insulin-
stimulated PI3K and Akt activation and its association with p21 
it is not hard to imagine that PANDER, itself, may play a role 
in the development and/or progression of cancer. New studies 
have shown PANDER to be downregulated in gastric cancer patients 
[184]. Another study identified PANDER to be the fourth most 
highly downregulated transcript in prostate cancer patients 
[185]. Preliminary data from our lab, in collaboration with Dr. 
Meera Nanjundan, suggest downregulation of PANDER among several 
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ovarian cancer cell lines when compared to normal ovarian 
surface epithelial cells (Figure 26). A very similar result was 
identified in oral squamous carcinoma cell lines when compared 
to normal oral squamous cells [186]. Conversely, a non-secretory 
form of PANDER has been shown to increase invasion and migration 
in human colon cancer cells [187]. This suggests that PANDER my 
play a duel role in cancer pathogenesis or that secretory and 
non-secretory may serve different purposes. There have been no 
other studies to date investigating what role PANDER may be 
playing in cancer cell’s ability to develop and proliferate. The 
role of PANDER in human cancers could be causative of cancer; it 
could be supportive of a previously established cancer; or it 
could even be inhibitory as part of the body’s defense against 
cancer cells. PANDER’s inhibition of known anti-apoptotic and 
pro-proliferative pathways suggests that PANDER may play an 
inhibitory role in cancer development and progression and that 
the downregulation of PANDER in patients promotes the growth and 
proliferation of cancer cells.  
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Figure 21: Overview of Transcription Factor Array. Biotinylated 
DNA oligonucleotide probes are mixed with hepatocyte nuclear 
extract. Transcription factors present in extract are then bound 
to probes and moved into columns where unbound probes are 
separated. Denaturation allows for the liberation of free probe, 
which is then hybridized to a membrane array containing 
consensus DNA binding sequences for 345 transcription factors. 
Biotin controls are located on the bottom and right of membrane 
to ensure equal distribution of extract. Adapted from Affymetrix 
(www.affymetrix.com).  
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Figure 22: Diagram of Protein/DNA ComboArray from Affymetrix. 
The Panomics Protein/DNA ComboArray from Affymetrix is spotted 
with 345 transcription factor consensus binding sequences. The 
grey rows and columns contain the biotinylated DNA positive 
controls for the assay. 
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Figure 23: Transcription Factor Array membranes for untreated 
and pander treated hepatocytes. Untreated (A) and 10 nM PANDER 
treated (B) membranes are shown. Row P and Column 24 represent 
biotinylated DNA positive controls. 
  
A	
B	
Untreated	
PANDER	Treated	
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Table 2: Differentially regulated proteins identified with 
Transcription Factor Array.  
 
 
**All data shown represent fold change from the untreated 
condition. 
  
Protein Fold	Change Protein Fold	Change
GATA-2 1375.13 E4F/ATF 32.08
CEBP 588.66 Cdx-2 25.17
E47 442.92 L-III	BP 24.23
PAX-6 371.69 WTI(2) 22.81
Sp-1 367.88 MRE 18.57
AP-3 320.81 ETF 17.27
CBF 276.47 MZF1 13.58
MUSF-1 192.61 SMAD-3/4 8.99
NF-E1/YY1 191.41 Antioxident	RE 8.55
MEF-1 184.20 PAX-5 7.61
PAX-8 144.26 E2 6.00
USF-1 125.00 EBP-40/45 4.55
TFIID 114.96 Ets 4.49
AhR/Amt 110.90 GATA-1	(1) 4.26
NFkB	(2) 101.48 c-Myb 3.47
PPAR 83.81 ADD-1 3.05
c-Rel 80.27 CTCF 2.51
ISRE(2) 79.97 AR 2.12
XBP-1 75.77 PYR 2.08
ADR-1 71.97 CCAC 1.46
RAR/DR-5 68.49 HMG 1.45
CCAAT 68.31 EGR 1.35
EGR-1(2) 67.67 LyF 1.08
MBP-1(1) 63.77 E12 0.98
PRE 61.75 CEF-2 0.82
kBF-A 59.71 WTI(1) 0.76
ISGF 57.16 TR 0.40
NF-A3 55.09 MT-Box 0.40
E2F-1(1) 54.25 c-Myc 0.34
TIF-I 54.12 TEF1 0.13
PAX-4 51.71 GATA-1	(2) 0.04
GATA-1/2 48.06
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Table 3: Top differentially regulated proteins 
 
 
  
Transcription Factor Exp. Value Function
GATA-2 1375.133 Hematopoietic development
CEBPA 588.663 Hepatocyte proliferation, gluconeogenesis
TCF3/E47 442.919 Liver/Pancreatic development, Cancer
PAX-6 371.695 CNS/Pancreatic developmemt
Sp-1 367.885 Hepatocyte proliferation
YBX1/CBF 276.467 Cancer
SAA1/MUSF-1 192.614 Inflammation
NF-E1/YY1 191.414 DNA damage response, cancer
PAX-8 144.256 Embryonic development, cancer
USF-1 124.996 Insulin signaling, lipogenesis
TEAD1/TEF1 -7.720 Cancer
MYC/c-Myc -2.905 Cancer
THRA/TR -2.485 Development
TNNC1/CEF-2 -1.215 Cardiac Muscle Contraction
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Table 4: Top diseases and disorders identified by IPA 
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Table 5: Top molecular and cellular functions identified by IPA 
 
 
 
 
  
 
 
 
 
Name p-value #Molecules
Gene Expression 7.28E-05 - 4.64E-35 41
Cellular Growth and Proliferation 6.15E-05 - 1.81E-20 42
Cell Death and Survival 6.04E-05 - 1.82E-19 40
Cellular Development 7.02E-05 - 2.96E-19 38
Cell Cycle 7.02E-05 - 3.27E-12 26
Physiological System Development and Function
Name p-value #Molecules
Hematological System Development and Function 7.02E-05 - 5.78E-19 30
Organismal Survival 2.38E-05 - 3.32E-17 34
Embryonic Development 6.92E-05 - 5.02E-16 36
Organismal Development 7.26E-05 - 5.02E-16 39
Hematopoiesis 7.02E-05 - 3.52E-15 24
Top Tox Functions
Assays: Clinical Chemistry and Hematology
Name p-value #Molecules
Increased Levels of Hematocrit 1.15E-03 - 1.15E-03 3
Increased Levels of Albumin 2.19E-03 - 2.19E-03 1
Increased Levels of ALT 1.09E-02 - 1.09E-02 1
Increased Levels of AST 1.31E-02 - 1.31E-02 1
Increased Levels of Red Blood Cells 2.07E-02 - 2.07E-02 2
Cardiotoxicity
Summary of Analysis - PANDEREvalIPA - 2015-10-12 02:53 PM
(c) 2000-2015 QIAGEN. All rights reserved. 3
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Table 6: Top development functions identified by IPA 
 
 
 
 
  
 
 
 
 
Name p-value #Molecules
Gene Expression 7.28E-05 - 4.64E-35 41
Cellular Growth and Proliferation 6.15E-05 - 1.81E-20 42
Cell Death and Survival 6.04E-05 - 1.82E-19 40
Cellular Development 7.02E-05 - 2.96E-19 38
Cell Cycle 7.02E-05 - 3.27E-12 26
Physiological System Development and Function
Name p-value #Molecules
Hematological System Development and Function 7.02E-05 - 5.78E-19 30
Organismal Survival 2.38E-05 - 3.32E-17 34
Embryonic Development 6.92E-05 - 5.02E-16 36
Organismal Development 7.26E-05 - 5.02E-16 39
Hematopoiesis 7.02E-05 - 3.52E-15 24
Top Tox Functions
Assays: Clinical Chemistry and Hematology
Name p-value #Molecules
Increased Levels of Hematocrit 1.15E-03 - 1.15E-03 3
Increased Levels of Albumin 2.19E-03 - 2.19E-03 1
Increased Levels of ALT 1.09E-02 - 1.09E-02 1
Increased Levels of AST 1.31E-02 - 1.31E-02 1
Increased Levels of Red Blood Cells 2.07E-02 - 2.07E-02 2
Cardiotoxicity
Summary of Analysis - PANDEREvalIPA - 2015-10-12 02:53 PM
(c) 2000-2015 QIAGEN. All rights reserved. 3
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Figure 24: Top liver toxicity functions identified by IPA. IPA 
analysis identified several liver toxicity functions associated 
with the proteins that were differentially regulated in PANDER 
treated hepatocytes. 
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Table 7: Top networks identified by IPA 
 
 
 
  
 
 
 
3 IL6 inflammation of organ -3.402
4 FOXO1 cellular homeostasis -4.536
5 IL6 cell viability of leukocytes -6.5
Top Networks
ID Associated Network Functions Score
1 Gene Expression, Cellular Development, Embryonic Development 28
2 Cellular Growth and Proliferation, Lymphoid Tissue Structure and Development, Cellular Development 23
3 Gene Expression, Cellular Development, Cellular Growth and Proliferation 23
4 Gene Expression, Carbohydrate Metabolism, Cellular Function and Maintenance 13
5 Cell-To-Cell Signaling and Interaction, Hematological System Development and Function, Immune CellTrafficking 7
Top Tox Lists
Name p-value Overlap
Liver Proliferation 5.15E-11  4.4 % 10/227
Liver Necrosis/Cell Death 8.11E-09  3.2 % 9/279
Aryl Hydrocarbon Receptor Signaling 5.70E-08  4.3 % 7/161
Increases Liver Hyperplasia/Hyperproliferation 8.57E-08  5.9 % 6/101
Cardiac Fibrosis 3.75E-06  3.1 % 6/192
Top Analysis-Ready Molecules
Exp Fold Change up-regulated
Molecules Exp. Value Exp. Chart
GATA2 1375.133
CEBPA 588.663
TCF3* 442.919
PAX6 371.695
Summary of Analysis - PANDEREvalIPA - 2015-10-12 02:53 PM
(c) 2000-2015 QIAGEN. All rights reserved. 5
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Figure 25: Gene expression, cellular development and embryonic 
development network. Several differentially regulated proteins 
were found to be associated with the gene expression, cellular 
development and embryonic development network. These factors 
interact with each other as well as other important proteins, 
such as PEPCK and the estrogen receptor. Red indicates an 
upregulation in response to PANDER treatment and green indicates 
a downregulation in response to PANDER treatment. Proteins in 
white were not identified in the TF Array, but are important for 
functions within this network. 
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Figure 26: PANDER protein levels in ovarian cancer cell lines.  
(A) Western blot for PANDER in several cell lines performed in 
collaboration with Dr. Meera Nanjundan. (B) Densitometry 
performed on ovarian cell lines, noncancerous cell line shown in 
white, cancerous cell lines shown in black. 
 
 
 
 
 
 
 
  
PANDER 
A
54
9 
T2
9 
O
VC
A
R
8 
H
15
7 
M
C
F7
 
M
D
A 
M
B
 4
68
 
SK
O
V3
 
H
EY
 
A
sp
c-
1 
M
ia
Pa
C
a2
 
B
xp
c3
 
Pa
nc
-1
 
M
D
A 
M
B
 2
31
 
T8
0 
O
VC
A
42
9 
T4
7D
 
U
20
S 
Lung Ovarian Breast Pancreatic Bone 
GAPDH 
A 
26 kDa 
37 kDa 
129 
 
 
 
 
 
 
 
 
Figure 25: continued. 
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Figure 27: PANDER’s activity within the insulin signaling 
pathway. The binding of insulin to the insulin receptor 
activates two major downstream pathways: MAPK and PI3K signaling 
pathways [163]. PANDER inhibits insulin-stimulated activation of 
the PI3K pathway, thereby reducing Akt’s inhibition of apoptosis 
and cell cycle arrest and promotion of cell proliferation. MAPK 
signaling, which promotes cell growth and survival, has been 
shown to inhibit glucose-induced PANDER expression [84]. 
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CHAPTER 6: IMPLICATIONS AND FUTURE DIRECTIONS 
 
 
Summary of Major Findings 
Type 2 Diabetes is characterized by insulin resistance, 
resulting in an overall state of hyperglycemia, hyperinsulinemia 
and hyperlipidemia [5]. Recent research has implicated several 
cytokines and other signaling molecules in contributing to the 
development and progression of this insulin resistant state 
[10]. Pancreatic-Derived Factor (PANDER) is one such molecule 
that has been identified as having a potential role in insulin 
resistance and T2D. The primary focus of previous PANDER 
research has been on its expression from and function within the 
pancreas; however, the liver has been identified as a novel 
tissue for expression [67]. This dissertation focuses primarily 
on the regulation of PANDER expression in the liver. As 
presented in Chapter 3, we confirmed both the activity of the 
PANDER promoter and the presence of PANDER protein within liver 
tissues. We were also able to identify a novel transcriptional 
start site 26 bp upstream of the translational start codon. This 
is in contrast to the pancreatic start site, previously 
identified 520 bp upstream of the translational start codon 
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[111]. This may suggest that there are differential mechanisms 
for the regulation of expression of PANDER within these two 
tissues. Further, we identified the minimal element for baseline 
promoter expression as being the -293/-3 region, with the -193/-
93 region being essential for promoter activity. This region is 
also the minimal element responsible for the high level of 
glucose-stimulated activity of the PANDER promoter. Insulin and 
palmitate were not found to have any stimulatory effect. PANDER 
mRNA levels in primary hepatocytes mirror the promoter studies, 
significantly increasing in a dose-dependent manner with glucose 
treatment.  
 
Within the identified minimal element of the PANDER promoter 
there are several putative transcription factor binding sites 
[118]. There are three E-Boxes within this region that are of 
particular interest as E-Boxes are known binding sites for 
Carbohydrate Responsive Element Binding Protein (ChREBP) [95]. 
ChREBP is a known glucose-responsive transcription factor within 
the liver and is involved in the activation of transcription of 
several genes associated with lipogenesis [99]. We investigated 
the impact of ChREBP expression on the PANDER promoter and found 
that when ChREBP is expressed in a liver cell line, PANDER 
promoter activity is upregulated in both the fasted and fed 
states. We have also identified the -193/-3 region of the PANDER 
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promoter as being bound by ChREBP under glucose-stimulatory 
conditions using chromatin immunoprecipitation in primary 
hepatocytes. There is only one intact E-box within that region: 
E-box 3. Site-directed mutagenesis was used to remove E-box 3 
from the PANDER promoter. This mutant construct was 
significantly less active under baseline conditions and had a 
significantly reduced glucose-response. This suggests that E-box 
3 is important for PANDER promoter activity, particularly under 
glucose-stimulatory conditions, and that this may be the 
specific site for ChREBP binding. 
 
PANDER has not been studied in the liver with respect to its 
effect on transcription factor activity. In Chapter 5, we 
utilized a transcription factor array and evaluated the response 
of 345 different transcription factors in primary hepatocytes 
with PANDER treatment. We found that there were 63 
differentially regulated transcription factors: 55 were 
upregulated in response to PANDER treatment and 8 were 
downregulated. Ingenuity Pathway Analysis identified several of 
these transcription factors as having roles in cancer and/or 
development. Of particular interest was the significant 
upregulation of the CEBP transcription factor. CEBP has been 
shown to activate transcription of PEPCK [156]. PEPCK has been 
shown to be increased in the PANDER transgenic overexpressor 
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mouse and decreased in the PANDER knockout mouse [70, 77]. 
PANDER’s upregulation of CEBP is a novel finding and may 
implicate CEBP as an upstream factor resulting in the increased 
expression of PEPCK in the presence of elevated levels of 
PANDER. 
 
Chapter 3: Limitations of the Studies 
In Chapter 3 we investigated the regulation of PANDER in the 
liver by utilizing PANDER promoter constructs. In this respect, 
we are equating PANDER promoter activity with overall PANDER 
expression. We were able to confirm the association between 
PANDER promoter activity in response to glucose and PANDER mRNA 
expression in primary hepatocytes; however, we have not been 
able to confirm an upregulation of PANDER protein levels. This 
is primarily due to the lack of availability of reliable and 
specific PANDER antibodies for Western Blot or ELISA, 
particularly for cell culture lysate where protein concentration 
is low. We were able to show an increased trend of PANDER 
protein expression in response to glucose treatment in BNLCL2 
cells via ELISA, however expression was below the range of the 
standard curve and could not be accurately analyzed (data not 
shown). Further development of commercial antibodies for PANDER 
is necessary to confirm these trend in protein. 
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Chapter 5: Limitations of the Studies 
Our TF array data provides some useful insight into the effects 
that PANDER has on transcription factor networks and disease; 
however, there are some limitations to this assay. Although 
protein concentration was normalized when applied to the 
membranes and exposure time was the same during imaging, there 
is no normalization control on the membrane itself to account 
for potential differences in transcription factor binding or 
exposure time to assay reagents. The positive controls on the 
membrane only serve as confirmation that the hybridization 
occurred evenly across the membrane. As such, minimal increases 
or decreases in transcription factor expression between the 
untreated and PANDER treated groups may be due to differences in 
membrane handling and not differences in expression. Due to this 
possibility, all of the identified factors should be validated 
by other means, such as RT-PCR or traditional western blot. In 
addition, further investigation into PANDER’s expression in 
cancerous cell lines and tissues should be further evaluated 
based on the western blot showing decreased expression in 
cancerous versus normal ovarian epithelial cells to confirm the 
identified tend.  
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Future Directions 
The studies detailed in this dissertation have provided 
invaluable information regarding regulation of the PANDER 
promoter within the liver and how PANDER expression may be 
influencing transcription factor activity. This has provided a 
platform for future PANDER research; as there are several 
questions about PANDER that have yet to be addressed. 
 
Human PANDER promoter activity. All of the previous studies 
investigating the activity of the PANDER promoter have focused 
on the murine PANDER promoter and murine cell lines. Although 
the murine and human PANDER genes share 78% homology [110], it 
is unknown how the promoter may be differentially regulated in 
human tissues. As no human PANDER promoter constructs are known 
to exist, new constructs will need to be cloned into luciferase 
vectors and evaluated in a similar manner to how the murine 
promoter has been evaluated in the pancreas [111, 118] and in 
the liver [136].  
 
ChREBP regulation of PANDER in the liver. Our studies showed 
that ChREBP binds to the PANDER promoter and increases its 
activity. We also identified a putative binding site for ChREBP 
at E-box 3. Further research is necessary to confirm E-box 3 as 
the binding site for ChREBP. Electrophoretic Mobility Shift 
137 
Assay (EMSA) can be used to confirm the binding of ChREBP to the 
PANDER promoter and further narrow down its binding site. The 
PANDER mutant construct can also be used to determine if the 
exclusion of E-box 3 abrogates binding. In addition, further 
research is necessary to determine if E-boxes 1 and 2 are 
potential binding sites for ChREBP or other factors. To better 
understand ChREBP regulation of PANDER in an in vivo model, a 
ChREBP knockout mouse could be utilized. The ChREBP knockout 
mouse displays reduced lipogenesis and glycolysis [125, 131]; it 
would be interesting to see whether PANDER levels are also 
reduced when compared to WT mice. 
 
PANDER regulation in other cell types. PANDER has been studied 
primarily in the pancreas and liver; however, data suggests that 
PANDER is produced within several tissues. The work included in 
this dissertation identified robust expression of PANDER protein 
in the murine brain and minor expression within the ovary. There 
have been no studies to date that have investigated the 
regulation or function of PANDER in these tissues. A similar 
promoter study to that performed in this dissertation could be 
performed in the brain and ovary, as well as other tissues to 
evaluate the activity and potential regulation of the PANDER 
promoter. The TF array data detailed in Chapter 5 suggests many 
potential functions for PANDER outside of its traditional role 
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in metabolic signaling, which may speak to PANDER’s function in 
tissues other than the pancreas and liver.   
 
Other regulatory mechanisms of PANDER. Research into the 
regulation of PANDER has focused almost entirely on its 
regulation by transcription factors. There have been no major 
studies into how PANDER may be regulated by micro RNAs, histone 
modification or other epigenetic mechanisms. There has been a 
single abstract suggesting that the PANDER gene is silenced by 
epigenetic modification in gastric cancer cell lines, however, 
no future studies have been published based on this abstract 
[188]. We have demonstrated that PANDER has multiple cell-
specific transcriptional start sites. One study found that 
transcription start sites that are located far downstream are 
more responsive to transcription factors, whereas upstream start 
sites may be regulated more by chromatin organization and other 
factors [121]. This suggests that while the liver-specific start 
site may be more highly regulated by transcription factors, 
while the pancreas-specific start site (520 bp upstream of the 
TSC) may be regulated by other factors.  
 
CEBP, PEPCK and PANDER. Our transcription factor array 
identified 63 differentially regulated TFs in response to PANDER 
treatment. One of the most highly upregulated transcription 
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factors in response to PANDER treatment was CEBP. CEBP has been 
shown to activate the transcription of PEPCK [156], a 
gluconeogenic protein that has also been shown to be upregulated 
in response to increased PANDER levels [70]. This suggests that 
perhaps CEBP represents an upstream factor in the PANDER 
activation of PEPCK and gluconeogenesis. Further research is 
necessary to validate the PANDER associated upregulation of CEBP 
and whether this is directly activating the transcription of 
PEPCK.  
 
PANDER and cancer. Several of the differentially regulated 
transcription factors identified with our TF array appeared to 
be involved in cancer pathogenesis when analyzed using IPA. We 
also showed that PANDER protein levels appeared to be decreased 
in ovarian cancer cell lines when compared to a normal ovarian 
epithelial cell line. This result was very similar to the 
downregulation of PANDER that was identified in oral squamous 
carcinoma cell lines [186]. There are a number of studies that 
could be performed to further elucidate the role that PANDER may 
have in cancer, or its potential as a cancer biomarker. In 
vitro, cancer cells could be transiently transfected with a 
PANDER expression plasmid, similar to what was performed in 
human colon cancer cell lines [187]. These cells could then be 
evaluated for overall cell viability, invasion and migration. 
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PANDER expression could also be silenced by creating an siRNA 
molecule specific to the PANDER gene. These cells could be 
similarly evaluated. In vivo, the PANDER knockout and transgenic 
mouse models could be utilized for tumor models to assess the 
viability of tumors when there is an absence or abundance of 
PANDER. PANDER’s role in cancer could be evaluated under various 
conditions as well as with different cell/tumor types, as well.  
 
PANDER receptor. While PANDER has been shown to bind to the 
liver cell membrane [84], its specific receptor remains 
unidentified. One method for identifying a PANDER receptor would 
be to prepare a plasmid cDNA library from liver cells. This 
plasmid library could then be transfected and expressed in a 
cell line that does not normally express the PANDER receptor. 
Expression of the PANDER receptor would be identified through 
binding of radiolabeled or fluorescently labeled PANDER protein. 
The receptor protein can then be identified by the cDNA that was 
expressed. Expression systems can then be used to synthesize 
receptor from its cDNA and study its properties.  
 
PANDER as a therapeutic target for T2D. T2D is characterized by 
the progressive loss of glucose tolerance, resulting in 
prolonged hyperglycemia. Impaired glucose tolerance and fasting 
hyperglycemia are already present in many pre-diabetic patients 
141 
and these factors represent strong risk factors for the eventual 
development of T2D [189]. Fasting hyperglycemia in T2D is also 
associated with an increase in hepatic glucose production [190]. 
Our PANDER transgenic mouse model displays a phenotype with 
multiple metabolic abnormalities that is similar to that of T2D 
[70]. In addition, patients with T2D appear to have higher 
circulating levels of PANDER [109]. Not only do diabetic 
patients display hyperglycemia, hyperinsulinemia and 
hyperlipidemia; they also appear to display hyperPANDERemia. 
This implicates PANDER as a potential therapeutic target for the 
treatment of T2D. Previous studies have shown that hepatic 
PANDER siRNA knockdown in db/db mice significantly decreases 
hepatic steatosis, insulin resistance and fasting hyperglycemia 
[67]. These data suggest that a possible T2D therapeutic could 
be created to inhibit hepatic PANDER signaling, thereby 
decreasing HGP and improving insulin sensitivity.  
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